<SEC-DOCUMENT>0001104659-24-115372.txt : 20241107
<SEC-HEADER>0001104659-24-115372.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107170226
ACCESSION NUMBER:		0001104659-24-115372
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241107
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ClearPoint Neuro, Inc.
		CENTRAL INDEX KEY:			0001285550
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				582394628
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34822
		FILM NUMBER:		241436903

	BUSINESS ADDRESS:	
		STREET 1:		120 S. SIERRA AVENUE
		STREET 2:		SUITE 100
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		9499006833

	MAIL ADDRESS:	
		STREET 1:		120 S. SIERRA AVENUE
		STREET 2:		SUITE 100
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MRI INTERVENTIONS, INC.
		DATE OF NAME CHANGE:	20110714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SURGIVISION INC
		DATE OF NAME CHANGE:	20091106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SURGI VISION INC
		DATE OF NAME CHANGE:	20040331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2427351d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:clpt="http://clearpointneuro.com/20241107">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_clpt_clearpointneuro.com_20241107 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20241107_20241107 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001285550 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000004" name="dei:EntityCentralIndexKey">0001285550</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="clpt-20241107.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285550</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-07</xbrli:startDate>
        <xbrli:endDate>2024-11-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20241107__20241107_z3qgTToge9c6"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span> </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR 15(d) of the
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report&#160;(Date of earliest event
reported):  <span id="xdx_906_edei--DocumentPeriodEndDate_c20241107__20241107_z9I70qTDA1C2"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 7, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20241107__20241107_zmGgCyoSe50g"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000011" name="dei:EntityRegistrantName">CLEARPOINT NEURO, INC.</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20241107__20241107_zxw4nGa3aarh"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20241107__20241107_zQqOpbta51ec"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000013" name="dei:EntityFileNumber">001-34822</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20241107__20241107_zK1XNFbBR7Bl"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">58-2394628</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(State or other jurisdiction</b> <b><br/>
of incorporation)</b> </td>
    <td style="text-align: center"><b>(Commission</b> <b><br/>
File Number)</b> </td>
    <td style="text-align: center"><b>(I.R.S. Employer</b> <b><br/>
Identification Number)</b> </td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20241107__20241107_znXNSNuYcepd"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000015" name="dei:EntityAddressAddressLine1">120 S. Sierra Ave., Suite 100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressCityOrTown_c20241107__20241107_zzkyuqKdXpQi"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000016" name="dei:EntityAddressCityOrTown">Solana Beach</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20241107__20241107_zCpOh0BRUT4b"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20241107__20241107_zHtSa6gt9GD8"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000018" name="dei:EntityAddressPostalZipCode">92075</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, zip
code) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_909_edei--CityAreaCode_c20241107__20241107_zOg2wwSehZOd"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000019" name="dei:CityAreaCode">888</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20241107__20241107_zivJtsMfKEig"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000020" name="dei:LocalPhoneNumber">287-9109</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20241107__20241107_z9JIsYyH5o6k"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;</td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--SolicitingMaterial_c20241107__20241107_zUxi5kU9Jqc1"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20241107__20241107_zCeapKT0X0be"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20241107__20241107_ztGeJIfnfOT7"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; vertical-align: middle; width: 41%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: middle; width: 26%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: middle; width: 33%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which<br/>
registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20241107__20241107_zYfMJIED9dDl"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000025" name="dei:Security12bTitle">Common Stock, $0.01 par value per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20241107__20241107_zsOjVzRiUfJf"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000026" name="dei:TradingSymbol">CLPT</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--SecurityExchangeName_c20241107__20241107_zmgJhQIhpzCg"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -0.05pt">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20241107__20241107_zaxTN7Zwcqxg"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.01.</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November&#160;7, 2024,
ClearPoint Neuro,&#160;Inc. (the &#8220;Company&#8221;) entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales
Agreement&#8221;) with Stifel, Nicolaus&#160;&amp; Company,&#160;Incorporated, as sales agent (the &#8220;Agent&#8221;), to sell shares
of the Company&#8217;s common stock, par value $0.01 per share (&#8220;Common Stock&#8221;) having aggregate sales proceeds of up to $50
million (the &#8220;Shares&#8221;), from time to time, through an &#8220;at the market offering&#8221; program, as defined in as defined
in Rule&#160;415(a)(4)&#160;under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Any Shares sold under the
Sales Agreement will be issued pursuant to the Company&#8217;s registration statement on Form&#160;S-3 (File No.&#160;333-275476), which
was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on November&#160;20, 2023, the base prospectus filed
as part of such registration statement and the prospectus supplement filed by the Company with the SEC on the date hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms and conditions
of the Sales Agreement, the Agent will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable
state and federal laws, rules&#160;and regulations, and the rules&#160;of the Nasdaq Capital Market, to sell the Shares from time to time
based upon the Company&#8217;s instructions for the sales, including any price, time or size limits specified by the Company. Under the
Sales Agreement, the Agent may sell the Shares by any method deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415(a)(4)&#160;under
the Securities Act. The Agent&#8217;s obligations to sell the Shares under the Sales Agreement are subject to satisfaction of certain
conditions, including customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay Agent a commission of up to 3.0% </span>of the gross sales price of the Shares for amounts of Shares sold from
time to time pursuant to the Sales Agreement and to provide Agent with customary indemnification and contribution rights, including for
liabilities under the Securities Act. The Company also will reimburse the Agent for certain specified expenses in connection with entering
into the Sales Agreement. The Sales Agreement contains customary representations and warranties and conditions to the placements of the
Shares pursuant thereto. The Company is not obligated to sell any Shares under the Sales Agreement and may at any time suspend solicitation
and offers under the Sales Agreement. The Sales Agreement may be terminated by the Company at any time by giving written notice to the
Sales Agent for any reason or by the Sales Agent at any time by giving written notice to the Company for any reason or immediately under
certain circumstances, and shall automatically terminate upon the issuance and sale of all Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description
of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which
is filed herewith as Exhibit&#160;1.1 to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Bass, Berry&#160;&amp; Sims PLC relating to the legality of the issuance and sale of the Shares that may be sold
pursuant to the Sales Agreement is filed herewith as Exhibit&#160;5.1 </span>to this Current Report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form&#160;8-K
shall not constitute an offer to sell or the solicitation of an offer to buy any securities under the Sales Agreement, nor shall there
be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01.</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(d)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
No.</b></span></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 90%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="tm2427351d2_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><a href="tm2427351d2_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At-The-Market Equity Offering Sales Agreement, dated November&#160;7, 2024, by and between the Company and Stifel, Nicolaus&#160;&amp; Company,&#160;Incorporated.</span></a></td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="tm2427351d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><a href="tm2427351d2_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Bass, Berry&#160;&amp; Sims PLC</span></a></td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><a href="tm2427351d2_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><a href="tm2427351d2_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Bass, Berry&#160;&amp; Sims PLC (included in Exhibit&#160;5.1).</span></a></td></tr>
  <tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt">Date: November&#160;7, 2024</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><b>CLEARPOINT NEURO,&#160;INC.</b></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt; width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%">&#160;</td>
    <td style="font-size: 10pt; text-align: left; width: 45%">&#160;</td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">By:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">/s/ Danilo D&#8217;Alessandro</td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Name:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Danilo D&#8217;Alessandro</td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Title:</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUzFXnxMSiKLEIletxxjSXdkdrP8pP6yTYmGgWG499wrhC9y2qgWGc6rsoAKu76VFqHEBhn1FZ0j2+5ScLfEmzKWpbbT+wMzcgw6ZhnEycUJk3VQBusUomgRLhdxAmGSRgkc98L76hnpRtWorZItSF3DkalnhVbyOCdU8kWaunGqOiEbRdrFBeEsvyEOoxgONMgn8d1AUWTC86fxRM706J1r/bKovySsW+xcnZnp/3ofBdpKiw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2427351d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B>Exhibit&nbsp;1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CLEARPOINT NEURO,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock<BR>
($0.01 par value per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5in; text-align: right">November&nbsp;7, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STIFEL, NICOLAUS&nbsp;&amp; COMPANY,&nbsp;INCORPORATED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One South Street, 15<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baltimore, Maryland 21202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ClearPoint Neuro,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to
or through Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated (&ldquo;Stifel Nicolaus&rdquo;), as sales agent and/or principal (&ldquo;<U>Agent</U>&rdquo;),
shares (the &ldquo;<U>Shares</U>&rdquo;<I>) </I>of the Company&rsquo;s common stock, $0.01 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;),
having an aggregate offering price of up to $50,000,000 on the terms set forth in Section&nbsp;2 of this At-The-Market Equity Offering
Sales Agreement (the &ldquo;<U>Agreement</U>&rdquo;). The Company agrees that whenever it determines to sell Shares directly to the Agent
as principal, it will enter into a separate agreement with the Agent (each, a &ldquo;<U>Terms Agreement</U>&rdquo;) in substantially the
form of Annex I hereto, relating to such sale in accordance with Section&nbsp;3 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1. <U>Representations and Warranties</U>.
The Company represents and warrants to the Agent that as of the date of this Agreement, any applicable Registration Statement Amendment
Date (as defined in Section&nbsp;3 below), each Company Periodic Report Date (as defined in Section&nbsp;3 below), each Applicable Time
(as defined in Section&nbsp;1(a)&nbsp;below) and each Settlement Date (as defined in Section&nbsp;2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Registration Requirements</U>. The Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
a registration statement under the Securities Act of 1933, as amended (the &ldquo;<U>1933 Act</U>&rdquo;), on Form&nbsp;S-3 (File No.&nbsp;333-275476)
in respect of the Company&rsquo;s Common Stock (including the Shares) (collectively, the &ldquo;<U>Securities</U>&rdquo;) not declared
effective by the Commission earlier than three years prior to the date hereof; such registration statement, and any post-effective amendment
thereto, has become effective; and no stop order suspending the effectiveness of such registration statement or any part thereof has
been issued and no proceeding for that purpose has been initiated or, to the knowledge of the Company, threatened by the Commission (the
base prospectus filed as part of such registration statement, in the form in which it has most recently been filed with the Commission
on or prior to the date of this Agreement, is hereinafter called the &ldquo;<U>Basic Prospectus</U>&rdquo;; the various parts of such
registration statement, including all exhibits thereto and any prospectus supplement relating to the Shares that is filed with the Commission
and deemed by virtue of Rule&nbsp;430B to be part of such registration statement, each as amended at the time such part of the registration
statement became effective, including any post-effective amendments thereto, are hereinafter collectively called the &ldquo;<U>Registration
Statement</U>&rdquo;; the prospectus supplement specifically relating to the Shares prepared and filed with the Commission pursuant to
Rule&nbsp;424(b)&nbsp;under the 1933 Act is hereinafter called the &ldquo;<U>Prospectus Supplement</U>&rdquo;; the Basic Prospectus,
as amended and supplemented by the Prospectus Supplement, is hereinafter called the &ldquo;<U>Prospectus</U>&rdquo;; any reference herein
to the Basic Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item 12 of Form&nbsp;S-3 under the 1933 Act; any reference to any amendment or supplement to the Basic
Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration
Statement, any prospectus supplement relating to the Shares filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the 1933
Act and any documents filed under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>1934 Act</U>&rdquo;), and the rules&nbsp;and
regulations of the Commission thereunder (the &ldquo;<U>1934 Act Regulations</U>&rdquo;), and incorporated therein, in each case after
the date of the Basic Prospectus, the Prospectus Supplement or the Prospectus, as the case may be; any reference to any amendment to
the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;of the 1934 Act after the effective date of the Registration Statement that is incorporated by reference in the Registration
Statement; and any &ldquo;issuer free writing prospectus&rdquo; as defined in Rule&nbsp;433 under the 1933 Act relating to the Shares
is hereinafter called an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No order preventing or suspending the use of the
Basic Prospectus, the Prospectus Supplement or any Issuer Free Writing Prospectus has been issued by the Commission, and the Basic Prospectus
and the Prospectus Supplement, at the time of filing thereof, conformed in all material respects to the requirements of the 1933 Act and
the rules&nbsp;and regulations of the Commission thereunder (the &ldquo;<U>1933 Act Regulations</U>&rdquo;) and did not contain an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the purposes of this Agreement, the &ldquo;<U>Applicable
Time</U>&rdquo; means, with respect to any Shares, the time of sale of such Shares pursuant to this Agreement; the Prospectus and the
applicable Issuer Free Writing Prospectus(es) issued at or prior to such Applicable Time, taken together (collectively, and, with respect
to any Shares, together with the public offering price of such Shares, the &ldquo;<U>General Disclosure Package</U>&rdquo;) as of each
Applicable Time and each Settlement Date, will not include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each
applicable Issuer Free Writing Prospectus will not conflict with the information contained in the Registration Statement, the Prospectus
Supplement or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the General Disclosure
Package as of such Applicable Time, will not include any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Incorporation
of Documents by Reference</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and
the Prospectus, when they became effective or were filed with the Commission, as the case may be, complied in all material respects with
the requirements of the 1934 Act and the 1934 Act Regulations, and, when read together with the other information in the Prospectus, (a)&nbsp;at
the time the Registration Statement became effective, (b)&nbsp;at the time the Prospectus was issued and (c)&nbsp;on the date of this
Agreement, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Independent
Accountants</U>. The accountants who certified the financial statements and supporting schedules included in the Registration Statement
are independent public accountants as required by the 1933 Act and the 1933 Act Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Financial
Statements</U>. The financial statements included or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of
the Company and its consolidated Subsidiaries (as defined below) at the dates indicated and the statement of operations, stockholders&rsquo;
equity and cash flows of the Company and its consolidated Subsidiaries for the periods specified; said financial statements have been
prepared in conformity with generally accepted accounting principles in the United States (&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent
basis throughout the periods involved. The supporting schedules, if any, present fairly, in all material respects, in accordance with
GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the
Prospectus present fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that
of the audited financial statements included or incorporated by reference in the Registration Statement. All disclosures contained in
the Registration Statement, the General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the Commission) comply with Regulation G of the
1934 Act and Item 10 of Regulation S-K of the 1933 Act, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Material Adverse Change in Business</U>. Since the respective dates as of which information is given in the Registration Statement, the
General Disclosure Package or the Prospectus, except as otherwise stated therein, (A)&nbsp;there has been no material adverse change,
or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business
affairs or business prospects of the Company and its Subsidiaries considered as one enterprise, whether or not arising in the ordinary
course of business (a &ldquo;<U>Material Adverse Effect</U>&rdquo;), (B)&nbsp;there have been no transactions entered into by the Company
or any of its Subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its
Subsidiaries considered as one enterprise, and (C)&nbsp;there has been no dividend or distribution of any kind declared, paid or made
by the Company on any class of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Good
Standing of the Company</U>. The Company has been duly organized and is validly existing as a corporation in good standing under the laws
of the jurisdiction of its organization and has corporate power and authority to own, lease and operate its properties and to conduct
its business as described in the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly
qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification
is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify
or to be in good standing would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Good
Standing of Subsidiaries</U>. Each subsidiary listed on Schedule 1 hereto (each a &ldquo;<U>Subsidiary</U>&rdquo; and, collectively, the
&ldquo;<U>Subsidiaries</U>&rdquo;) has been duly organized and is validly existing as a corporation in good standing under the laws of
the jurisdiction of its incorporation, has corporate power and authority to own, lease and operate its properties and to conduct its business
as described in the Prospectus and is duly qualified as a foreign corporation to transact business and is in good standing in each jurisdiction
in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except
where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect; except as otherwise disclosed
in the Registration Statement, all of the issued and outstanding capital stock of each such Subsidiary has been duly authorized and validly
issued, is fully paid and non-assessable and is owned by the Company, directly or through subsidiaries, free and clear of any security
interest, mortgage, pledge, lien, encumbrance, claim or equity; none of the outstanding shares of capital stock of any Subsidiary was
issued in violation of the preemptive or similar rights of any securityholder of such Subsidiary. The only subsidiaries, direct and indirect,
of the Company are the subsidiaries listed on Schedule 1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Capitalization</U>.
The shares of issued and outstanding Common Stock have been duly authorized and validly issued and are fully paid and non-assessable;
none of the outstanding shares of capital stock was issued in violation of the preemptive or other similar rights of any securityholder
of the Company. The Company&rsquo;s Common Stock has been registered pursuant to Section&nbsp;12(b)&nbsp;of the 1934 Act and is listed
on the Nasdaq Capital Market (&ldquo;<U>Nasdaq</U>&rdquo;), and the Company has taken no action designed to, or likely to have the effect
of, terminating the registration or listing of the Common Stock from Nasdaq, nor has the Company received any notification that the Commission
or Nasdaq is contemplating terminating such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization
of Agreements</U>. This Agreement and any Terms Agreement have been duly authorized by the Company. This Agreement has been, and any Terms
Agreement will be, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
and Description of Securities</U>. The Shares have been duly authorized and reserved for issuance and sale pursuant to this Agreement
and, when issued and delivered by the Company pursuant to this Agreement or any Terms Agreement against payment of the consideration set
forth herein, will be validly issued and fully paid and non-assessable; the Common Stock conforms to all statements relating thereto contained
in the Prospectus and such description conforms to the rights set forth in the instruments defining the same; no holder of the Shares
will be subject to personal liability by reason of being such a holder; and the issuance of the Shares is not subject to the preemptive
or other similar rights of any securityholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Defaults and Conflicts</U>. (a)&nbsp;Neither the Company nor any of its Subsidiaries is (i)&nbsp;in violation of its charter or by-laws;
or (ii)&nbsp;in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract,
indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any
of its Subsidiaries is a party or by which it or any of them may be bound, or to which any of the property or assets of the Company or
any Subsidiary is subject (collectively, &ldquo;<U>Agreements and Instruments</U>&rdquo;); and (b)(i)&nbsp;and the execution, delivery
and performance of this Agreement or of any Terms Agreement and the consummation of the transactions contemplated herein or in any Terms
Agreement and in the Registration Statement (including the issuance and sale of the Shares and the use of the proceeds from the sale of
the Shares as described in the Prospectus under the caption &ldquo;Use of Proceeds&rdquo;) and compliance by the Company with its obligations
hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice
or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result
in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any Subsidiary pursuant
to, the Agreements and Instruments, (ii)&nbsp;nor will such action result in any violation of the provisions of the charter or by-laws
of the Company or any Subsidiary, (iii)&nbsp;nor will such action result in any violation of any applicable law, statute, rule, regulation,
judgment, order, writ or decree of any government, government instrumentality or court, domestic or foreign,&nbsp;including the U.S. Food
and Drug Administration (the &ldquo;<U>FDA</U>&rdquo;), having jurisdiction over the Company or any Subsidiary or any of their assets,
properties or operations (each, a &ldquo;<U>Governmental Entity</U>&rdquo;) except, in the case of clauses (a)(ii), (b)(i)&nbsp;and (b)(iii)&nbsp;above,
for any such violation or default that would not, singularly or in the aggregate, have a Material Adverse Effect. As used herein, a &ldquo;<U>Repayment
Event</U>&rdquo; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any
person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such
indebtedness by the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company or any Subsidiary exists or, to the knowledge of the Company,
is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any Subsidiary&rsquo;s
principal suppliers, manufacturers, customers or contractors that could have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Proceedings</U>. There is no action, suit, proceeding, inquiry or investigation before or brought by any court or Governmental Entity,
now pending, or, to the knowledge of the Company, threatened, against or affecting the Company or any Subsidiary, which is required to
be disclosed in the Registration Statement or the Prospectus (other than as disclosed therein), or which would reasonably be expected
to result in a Material Adverse Effect, or which might materially and adversely affect the properties or assets thereof, taken as a whole,
or the consummation of the transactions contemplated in this Agreement or any Terms Agreement or the performance by the Company of its
obligations hereunder or thereunder; the aggregate of all pending legal or governmental proceedings to which the Company or any Subsidiary
is a party or of which any of their respective property or assets is the subject which are not described in the Registration Statement
or the Prospectus, including ordinary routine litigation incidental to the business, would not reasonably be expected to result in a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Registration Statement or the Prospectus
or the documents incorporated by reference therein or to be filed as exhibits thereto which have not been so described and filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Possession
of Intellectual Property</U>. The Company and its Subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent
rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively, &ldquo;<U>Intellectual
Property</U>&rdquo;) necessary to carry on the business now operated by them, except to the extent that the failure to own or possess
adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, and neither the Company nor any of its Subsidiaries has received any notice or is otherwise aware of any infringement
of or conflict with asserted rights of others with respect to any Intellectual Property or of any facts or circumstances which would render
any Intellectual Property invalid or inadequate to protect the interests of the Company or any of its Subsidiaries therein except that
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>FDA
Compliance</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and
its Subsidiaries: (A)&nbsp;are and at all times have been in full compliance with all statutes, rules, regulations, or guidances applicable
to the Company and its Subsidiaries and the ownership, testing, research, design, development, manufacture, packaging, processing, use,
distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or
distributed by the Company (&ldquo;<U>Applicable Laws</U>&rdquo;), except where such non-compliance would not result, singly or in the
aggregate, in a Material Adverse Effect; (B)&nbsp;have not received any FDA Form&nbsp;483, notice of adverse finding, warning letter,
untitled letter or other correspondence or notice from any Governmental Entity alleging or asserting noncompliance with any Applicable
Laws or any licenses, certificates, approvals, clearances, authorizations, registrations, permits and supplements or amendments thereto
required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;) which has not been remedied by the Company and its Subsidiaries
or except where such noncompliance if not remedied would not, singly or in the aggregate, result in a Material Adverse Effect; (C)&nbsp;possess
all Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any
term of any such Authorizations; (D)&nbsp;have not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any Governmental Entity or third party alleging that any product operation or activity is in violation
of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Entity or third party is considering any such
claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;have not received notice that any Governmental Entity
has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge
that any such Governmental Entity is considering such action; and (F)&nbsp;have filed, obtained, maintained or submitted all reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws
or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission),
except where the failure to file, obtain, maintain or submit such documents would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Clinical
Studies</U>. The studies, tests and preclinical and clinical trials conducted by or on behalf of the Company and its Subsidiaries that
are material to the Company and its Subsidiaries taken as a whole were and, if still pending, are, in all material respects, being conducted
in accordance with experimental protocols, procedures and controls pursuant to accepted professional and scientific standards and all
Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations
at 21 C.F.R. Parts 50, 54, 56, 58 and 812, the approved Investigational Device Exemption applications, and other applicable federal, state,
local or foreign government or regulatory requirements, and the rules, regulations, requirements, and guidelines regarding human subject
protections; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure
Package and the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests
and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company
is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test,
or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed
in the context in which such results are described and the clinical state of development; and neither the Company nor any of its Subsidiaries
have received any notices or correspondence from any Governmental Entity requiring the termination, suspension or material modification
of any studies, tests or preclinical or clinical trials conducted or being conducted by or on behalf of the Company or any of its Subsidiaries
that are material to the Company and its Subsidiaries taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Manufacturing
Practices</U>. All the manufacturing facilities and operations performed by or on behalf of the Company and its subsidiaries are being
conducted in all material respects in compliance with all applicable statutes, rules, regulations and policies of the FDA and, to the
extent applicable, counterpart regulations in the European Union and all other countries where compliance is required. The Company and
its subsidiaries are in compliance in all material respects with all reporting requirements under Applicable Laws, including, but not
limited to, medical device reports (as defined by 21 C.F.R. Part&nbsp;803), reports of corrections and removals (as defined by 21 C.F.R.
Part&nbsp;806), and the reporting and recordkeeping requirements under the Quality System regulation of the FDA, and counterpart regulations
and requirements in other countries where compliance is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with
the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement or any
Terms Agreement, except such as have been already obtained or as may be required under the 1933 Act or the 1933 Act Regulations or state
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Absence
of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company take, directly or
indirectly, any action which is designed to or which has constituted or which would be expected to cause or result in stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u</FONT>)
&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Possession of Licenses and Permits</U>. (i) The Company
and its Subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, &ldquo;<U>Governmental
Licenses</U>&rdquo;) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies necessary to conduct the
business now operated by them; (ii)&nbsp;the Company and its Subsidiaries are in compliance with the terms and conditions of all such
Governmental Licenses; (iii)&nbsp;all of the Governmental Licenses are valid and in full force and effect; and (iv)&nbsp;neither the
Company nor any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such Governmental
Licenses, except in the case of clauses (i)&nbsp;through (iii)&nbsp;where such failures, noncompliance or invalidity would not reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title
to Property</U>. The Company and its Subsidiaries have good and marketable title to all real property owned by the Company and its Subsidiaries
and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests,
claims, restrictions or encumbrances of any kind except such as (a)&nbsp;are described in the Prospectus, (b)&nbsp;do not, singly or in
the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such property
by the Company or any of its Subsidiaries or (c)&nbsp;would not reasonably be expected to have a Material Adverse Effect; and all of the
leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company
or any of its Subsidiaries holds properties described in the Prospectus, are in full force and effect, and neither the Company nor any
Subsidiary has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any
Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary
to the continued possession of the leased or subleased premises under any such lease or sublease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Company Act</U>. The Company is not required, and upon the issuance and sale of the Shares as herein contemplated and the application
of the net proceeds therefrom as described in the Prospectus will not be required, to register as an &ldquo;investment company&rdquo;
within the meaning of the Investment Company Act of 1940, as amended (the &ldquo;<U>1940 Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Environmental
Laws</U>. Except as described in the Prospectus, (A)&nbsp;neither the Company nor any of its Subsidiaries is in violation of any federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative
interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection
of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata)
or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively,
&ldquo;<U>Hazardous Materials</U>&rdquo;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), (B)&nbsp;the Company and its Subsidiaries
have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their
requirements, (C)&nbsp;there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters,
claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company
or any of its Subsidiaries and (D)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an
order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting
the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental Laws except those, in each of the cases described
in clauses (A), (B), (C)&nbsp;or (D)&nbsp;above, that would not, singularly or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Rights</U>. There are no persons with registration rights or other similar rights to have any securities registered pursuant to the Registration
Statement or otherwise registered by the Company under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accounting
Controls and Disclosure Controls</U>. The Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization;
(B)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific authorization;
and (D)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action
is taken with respect to any differences. Except as described in the Prospectus, since the end of the Company&rsquo;s most recent audited
fiscal year, there has been (1)&nbsp;no material weakness in the Company&rsquo;s internal control over financial reporting (whether or
not remediated) and (2)&nbsp;no change in the Company&rsquo;s internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and its consolidated Subsidiaries employ
disclosure controls and procedures that are designed to ensure that information required to be disclosed by the Company in the reports
that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission&rsquo;s rules&nbsp;and forms, and is accumulated and communicated to the Company&rsquo;s management, including its principal
executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>S-3
Eligibility</U>. (A)(i)&nbsp;At the time of filing the Registration Statement and (ii)&nbsp;at the time of the most recent amendment
thereto for the purposes of complying with Section&nbsp;10(a)(3)&nbsp;of the 1933 Act (whether such amendment was by post-effective amendment,
incorporated report filed pursuant to Section&nbsp;13 or 15(d)&nbsp;of the 1934 Act or form of prospectus), the </FONT>Company met the
then applicable requirements for use of Form&nbsp;S-3 under the 1933 Act and (B)&nbsp;at the earliest time after the filing of the Registration
Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under
the 1933 Act) of the Shares, the Company was not an &ldquo;ineligible issuer&rdquo; as defined in Rule&nbsp;405 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No Commissions</U>.
Neither the Company nor any of its Subsidiaries is a party to any contract, agreement or understanding with any person (other than as
contemplated by this Agreement or any Terms Agreement) that would give rise to a valid claim against the Company or any of its Subsidiaries
or the Agent for a brokerage commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Deemed
Representation</U>. Any certificate signed by any officer of the Company delivered to the Agent or to counsel for the Agent pursuant to
or in connection with this Agreement or any Terms Agreement shall be deemed a representation and warranty hereunder by the Company to
the Agent as to the matters covered thereby as of the date or dates indicated in such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with the Sarbanes-Oxley Act.</U> There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the
rules&nbsp;and regulations promulgated in connection therewith (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), including Section&nbsp;402
related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
of Taxes</U>. The Company and its Subsidiaries each (i)&nbsp;have timely filed all necessary federal, state, local and foreign tax returns,
and all such returns were true, complete and correct, (ii)&nbsp;have paid all federal, state, local and foreign taxes, for which it is
liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its Subsidiaries is obligated
to withhold from amounts owing to employees, creditors and third parties, and (iii)&nbsp;do not have any tax deficiency or claims outstanding
or assessed or, to its knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii)&nbsp;and
(iii)&nbsp;above, that would not, singularly or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Company and its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in
such amounts and covering such risks as is generally maintained by companies of established repute engaged in the same or similar business,
and all such insurance is in full force and effect. The Company has no reason to believe that it or any Subsidiary will not be able (A)&nbsp;to
renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions
as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse
Effect. Neither of the Company nor any Subsidiary has been denied any insurance coverage which it has sought or for which it has applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Statistical
and Market-Related Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package
and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and, where required, the
Company has obtained the written consent to the use of such data from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Foreign
Corrupt Practices Act</U>. Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate
or other person acting on behalf of the Company or any of its Subsidiaries is aware of or has taken any action, directly or indirectly,
that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules&nbsp;and regulations
thereunder (the &ldquo;<U>FCPA</U>&rdquo;), including, without limitation, making use of the mails or any means or instrumentality of
interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other
property, gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign official&rdquo; (as such term
is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention
of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the
FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure,
continued compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Money
Laundering Laws</U>. The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping
and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of
all jurisdictions, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any Governmental Entity (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;) and no action, suit or proceeding
by or before any Governmental Entity, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws
is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>OFAC</U>.
Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee, affiliate or person acting on behalf
of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department
(&ldquo;<U>OFAC</U>&rdquo;); and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2. <U>Sale and Delivery of Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the terms and conditions set forth herein, the Company agrees to issue and sell exclusively through the Agent acting as sales agent
or directly to the Agent acting as principal from time to time, and the Agent agrees to use its commercially reasonable efforts to sell
as sales agent for the Company, the Shares. Sales of the Shares, if any, through the Agent acting as sales agent or directly to the Agent
acting as principal may be made in negotiated transactions or transactions that are deemed to be &ldquo;at the market offerings&rdquo;
as defined in Rule&nbsp;415 under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Shares are to be sold on a daily basis or otherwise as shall be agreed to by the Company and the Agent on such trading day (other than
a day on which Nasdaq is scheduled to close prior to its regular weekday closing time, each, a &ldquo;<U>Trading Day</U>&rdquo;) on which
(i)&nbsp;the Company has satisfied its obligations under Section&nbsp;6 of this Agreement and (ii)&nbsp;the Company has instructed the
Agent to make such sales. For the avoidance of doubt, the foregoing limitation shall not apply to sales solely to employees or security
holders of the Company or its Subsidiaries, or to a trustee or other person acquiring such securities for the accounts of such persons
in which Stifel Nicolaus is acting for the Company in a capacity other than as Agent under this Agreement. On any Trading Day, the Company
may instruct the Agent by telephone (confirmed promptly by telecopy or email by any of the individuals from the Company set forth on Schedule
2 and shall be addressed to each of the individuals from Stifel Nicolaus, which confirmation will be promptly acknowledged by the Agent)
as to the maximum number of Shares to be sold by the Agent on such day (in any event not in excess of the number available for issuance
under the Prospectus and the currently effective Registration Statement) and the minimum price per Share at which such Shares may be sold.
Subject to the terms and conditions hereof, the Agent shall use its commercially reasonable efforts to sell as sales agent all of the
Shares so designated by the Company. The Company and the Agent each acknowledge and agree that (A)&nbsp;there can be no assurance that
the Agent will be successful in selling the Shares, (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other
person or entity if they do not sell Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts
consistent with its normal trading and sales practices and applicable law and regulations to sell such Shares as required by this Agreement,
and (C)&nbsp;the Agent shall be under no obligation to purchase Shares on a principal basis except as otherwise specifically agreed by
each of the Agent and the Company pursuant to a Terms Agreement. In the event of a conflict between the terms of this Agreement and the
terms of a Terms Agreement, the terms of such Terms Agreement will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding the foregoing, the Company
shall not authorize the issuance and sale of, and the Agent as sales agent shall not be obligated to use its commercially reasonable efforts
to sell, any Shares (i)&nbsp;at a price lower than the minimum price therefor authorized from time to time, or (ii)&nbsp;in a number in
excess of the number of Shares authorized from time to time to be issued and sold under this Agreement, in each case, by the Company&rsquo;s
board of directors, or a duly authorized committee thereof, and notified to the Agent in writing. In addition, the Company may, upon notice
to the Agent, suspend the offering of the Shares or the Agent may, upon notice to the Company, suspend the offering of the Shares with
respect to which the Agent is acting as sales agent for any reason and at any time; <U>provided</U>, <U>however</U>, that such suspension
or termination shall not affect or impair the parties&rsquo; respective obligations with respect to the Shares sold hereunder prior to
the giving of such notice. Any notice given pursuant to the preceding sentence may be given by telephone by any of the individuals from
the Company set forth on Schedule 2 (confirmed promptly by telecopy or email and shall be addressed to each of the individuals from Stifel
Nicolaus, which confirmation will be promptly acknowledged).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The gross sales price of any Shares sold
pursuant to this Agreement by the Agent acting as sales agent of the Company shall be the market price prevailing at the time of sale
for Shares sold by the Agent on Nasdaq or otherwise, at prices related to prevailing market prices or at negotiated prices. The compensation
payable to the Agent for sales of Shares with respect to which the Agent acts as sales agent shall be equal to up to 3.0% of the gross
sales price of the Shares for amounts of Shares sold pursuant to this Agreement. The Company may sell Shares to the Agent, acting as principal,
at a price agreed upon with the Agent at the relevant Applicable Time and pursuant to a separate Terms Agreement. The remaining proceeds,
after further deduction for any transaction fees imposed by any governmental, regulatory or self-regulatory organization in respect of
such sales, shall constitute the net proceeds to the Company for such Shares (the &ldquo;<U>Net Proceeds</U>&rdquo;). The Agent shall
notify the Company as promptly as practicable if any deduction referenced in the preceding sentence will be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If acting as sales agent hereunder, the
Agent shall provide written confirmation to the Company following the close of trading on Nasdaq, on each Trading Day on which Shares
are sold under this Agreement setting forth the number of Shares sold on such day, the aggregate gross sales proceeds of the Shares, the
aggregate Net Proceeds to the Company and the aggregate compensation payable by the Company to such Agent with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Under no circumstances shall the aggregate
offering price or number, as the case may be, of Shares sold pursuant to this Agreement and any Terms Agreement exceed the aggregate offering
price or number, as the case may be, of Shares of Common Stock (i)&nbsp;set forth in the preamble paragraph of this Agreement, (ii)&nbsp;available
for issuance under the Prospectus and the then currently effective Registration Statement or (iii)&nbsp;authorized from time to time to
be issued and sold under this Agreement or any Terms Agreement by the Company&rsquo;s board of directors, or a duly authorized committee
thereof, and notified to the Agent in writing. In addition, under no circumstances shall any Shares with respect to which the Agent acts
as sales agent be sold at a price lower than the minimum price therefor authorized from time to time by the Company&rsquo;s board of directors,
or a duly authorized committee thereof, and notified to the Agent in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Settlement
for sales of Shares pursuant to this Section&nbsp;2 will occur on the first business day that is also a Trading Day following the trade
date on which such sales are made, unless another date shall be agreed to in writing by the Company and the Agent (each such day, a &ldquo;<U>Settlement
Date</U>&rdquo;). On each Settlement Date, the Shares sold through the Agent for settlement on such date shall be delivered by the Company
to the Agent against payment of the Net Proceeds from the sale of such Shares. Settlement for all Shares shall be effected by book-entry
delivery of Shares to the Agent&rsquo;s account at The Depository Trust Company against payments by the Agent of the Net Proceeds from
the sale of such Shares in same day funds delivered to an account designated by the Company. If the Company shall default on its obligation
to deliver Shares on any Settlement Date, the Company shall (i)&nbsp;indemnify and hold the Agent harmless against any loss, claim or
damage arising from or as a result of such default by the Company and (ii)&nbsp;pay the Agent any commission to which it would otherwise
be entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
any other provision of this Agreement, the Company and the Agent agree that no sales of Shares shall take place, and the Company shall
not request the sale of any Shares, and the Agent shall not be obligated to sell, during any period in which the Company&rsquo;s insider
trading policy, as it exists on the date of the Agreement, would prohibit the purchases or sales of the Company&rsquo;s Common Stock by
its officers or directors, or during any other period in which the Company is, or could be deemed to be, in possession of material non-public
information; provided that, unless otherwise agreed between the Company and the Agent, for purposes of this paragraph (i)&nbsp;such period
shall be deemed, subject to any subsequent notice by the Company, to begin on the 15<SUP>th</SUP> day of the third month of the fiscal
quarter of the Company and end on the second full trading day after the public release of earnings data for such fiscal quarter or during
any other special trading suspension period declared by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
each Applicable Time, Settlement Date, Registration Amendment Date and each Company Periodic Report Date, the Company shall be deemed
to have affirmed each representation and warranty contained in this Agreement. Any obligation of the Agent to use its commercially reasonable
efforts to sell the Shares on behalf of the Company as sales agent shall be subject to the continuing accuracy of the representations
and warranties of the Company herein, to the performance by the Company of its obligations hereunder and to the continuing satisfaction
of the additional conditions specified in Section&nbsp;6 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3. <U>Covenants.</U> The Company agrees
with the Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
any period when the delivery of a prospectus is required in connection with the offering or sale of Shares (whether physically or through
compliance with Rule&nbsp;153 or 172, or in lieu thereof, a notice referred to in Rule&nbsp;173(a)&nbsp;under the 1933 Act), (i)&nbsp;to
make no further amendment or any supplement to the Registration Statement or the Prospectus prior to any Settlement Date which shall be
disapproved by the Agent promptly after reasonable notice thereof and to advise the Agent, promptly after it receives notice thereof,
of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the
Prospectus has been filed and to furnish the Agent with copies thereof, (ii)&nbsp;to file promptly all other material required to be filed
by the Company with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the 1933 Act, (iii)&nbsp;to file promptly all reports and any
definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c),
14 or 15(d)&nbsp;of the 1934 Act, (iv)&nbsp;to advise the Agent, promptly after it receives notice thereof, of the issuance by the Commission
of any stop order or of any order preventing or suspending the use of the Prospectus or other prospectus in respect of the Shares, of
the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding
for any such purpose, or of any request by the Commission for the amending or supplementing of the form of the Registration Statement
or the Prospectus or for additional information, and (v)&nbsp;in the event of the issuance of any such stop order or of any such order
preventing or suspending the use of the Prospectus in respect of the Shares or suspending any such qualification, to promptly use its
commercially reasonable efforts to obtain the withdrawal of such order; and in the event of any such issuance of a notice of objection,
promptly to take such reasonable steps as may be necessary to permit offers and sales of the Shares by the Agent, which may include, without
limitation, amending the Registration Statement or filing a new registration statement, at the Company&rsquo;s expense (references herein
to the Registration Statement shall include any such amendment or new registration statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Promptly
from time to time to take such action as the Agent may reasonably request to qualify the Shares for offering and sale under the securities
laws of such jurisdictions as the Agent may request and to comply with such laws so as to permit the continuance of sales and dealings
therein in such jurisdictions for as long as may be necessary to complete the sale of the Shares, provided that in connection therewith
the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction;
and to promptly advise the Agent of the receipt by the Company of any notification with respect to the suspension of the qualification
of the Shares for offer or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
any period when the delivery of a prospectus is required (whether physically or through compliance with Rules&nbsp;153 or 172, or in lieu
thereof, a notice referred to in Rule&nbsp;173(a)&nbsp;under the 1933 Act) in connection with the offering or sale of Shares, the Company
will make available to the Agent, as soon as practicable after the execution of this Agreement, and thereafter from time to time furnish
to the Agent, copies of the most recent Prospectus in such quantities and at such locations as the Agent may reasonably request for the
purposes contemplated by the 1933 Act. During any period when the delivery of a prospectus is required (whether physically or through
compliance with Rules&nbsp;153 or 172, or in lieu thereof, a notice referred to in Rule&nbsp;173(a)&nbsp;under the 1933 Act) in connection
with the offering or sale of Shares, and if at such time any event shall have occurred as a result of which the Prospectus as then amended
or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or,
if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus or to file under the 1934
Act any document incorporated by reference in the Prospectus in order to comply with the 1933 Act or the 1934 Act, to notify the Agent
and to file such document and to prepare and furnish without charge to the Agent as many written and electronic copies as the Agent may
from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission
or effect such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
make generally available to its securityholders as soon as practicable, but in any event not later than sixteen months after the effective
date of the Registration Statement (as defined in Rule&nbsp;158(c)&nbsp;under the 1933 Act), an earnings statement of the Company and
its Subsidiaries (which need not be audited) complying with Section&nbsp;11(a)&nbsp;of the 1933 Act and the rules&nbsp;and regulations
of the Commission thereunder (including, at the option of the Company, Rule&nbsp;158).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
pay the required Commission filing fees relating to the Shares within the time required by Rule&nbsp;456(b)(1)&nbsp;under the 1933 Act
without regard to the proviso therein and otherwise in accordance with Rules&nbsp;456(b)&nbsp;and 457(r)&nbsp;under the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
use the Net Proceeds received by it from the sale of the Shares pursuant to this Agreement and any Terms Agreement in the manner specified
in the General Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
connection with the offering and sale of the Shares, the Company will file with Nasdaq all documents and notices, and make all certifications,
required by Nasdaq of companies that have securities that are listed or quoted on Nasdaq and will maintain such listings or quotations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
not take, directly or indirectly, and to cause its affiliates to refrain from taking, any action designed to cause or result in, or that
has constituted or might reasonably be expected to constitute, under the 1934 Act or otherwise, the stabilization or manipulation of the
price of any securities of the Company to facilitate the sale or resale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
each Applicable Time, each Settlement Date, each Registration Statement Amendment Date (as defined below), each Company Periodic Report
Date (as defined below) and each date on which Shares are delivered to the Agent pursuant to a Terms Agreement, the Company shall be deemed
to have affirmed each representation, warranty, covenant and other agreement contained in this Agreement or any Terms Agreement. In each
Annual Report on Form&nbsp;10-K or Quarterly Report on Form&nbsp;10-Q filed by the Company in respect of any quarter in which sales of
Shares were made by or through the Agent under this Agreement or any Terms Agreement (each date on which any such document is filed, and
any date on which an amendment to any such document is filed, a &ldquo;<U>Company Periodic Report Date</U>&rdquo;), the Company shall
set forth with regard to such quarter the number of Shares sold through the Agent under this Agreement or any Terms Agreement and the
Net Proceeds received by the Company with respect to sales of Shares pursuant to this Agreement or any Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
commencement of the offering of Shares under this Agreement and each time the Shares are delivered to the Agent as principal on a Settlement
Date and promptly after each (i)&nbsp;date the Registration Statement or the Prospectus shall be amended or supplemented (other than (1)&nbsp;by
an amendment or supplement providing solely for the determination of the terms of the Shares, (2)&nbsp;in connection with the filing of
a prospectus supplement that contains solely the information set forth in Section&nbsp;3(i), (3)&nbsp;in connection with the filing of
any current reports on Form&nbsp;8-K (other than any current reports on Form&nbsp;8-K which contain financial statements, supporting schedules
or other financial data, including any current report on Form&nbsp;8-K under Item 2.02 of such form that is considered &ldquo;filed&rdquo;
under the 1934 Act) or (4)&nbsp;by a prospectus supplement relating to the offering of other securities (including, without limitation,
other shares of Common Stock)) (each such date, a &ldquo;<U>Registration Statement Amendment Date</U>&rdquo;) and (ii)&nbsp;Company Periodic
Report Date, the Company will furnish or cause to be furnished forthwith to the Agent a certificate dated the date of effectiveness of
such amendment or the date of filing with the Commission of such supplement or other document, as the case may be, in a form reasonably
satisfactory to the Agent to the effect that the statements contained in the certificate referred to in Section&nbsp;6(e)&nbsp;of this
Agreement which were last furnished to the Agent are true and correct at the time of such amendment, supplement or filing, as the case
may be, as though made at and as of such time (except that such statements shall be deemed to relate to the Registration Statement, the
General Disclosure Package and the Prospectus as amended and supplemented to such time) or, in lieu of such certificate, a certificate
of the same tenor as the certificate referred to in said Section&nbsp;6(e), but modified as necessary to relate to the Registration Statement
and the Prospectus as amended and supplemented, or to the document incorporated by reference into the Prospectus, to the time of delivery
of such certificate. As used in this paragraph, to the extent there shall be an Applicable Time on or following the date referred to in
clause (i)&nbsp;or (ii)&nbsp;above, promptly shall be deemed to be on or prior to the next succeeding Applicable Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
commencement of the offering of Shares under this Agreement and each time the Shares are delivered to the Agent as principal on a Settlement
Date, and promptly after each (i)&nbsp;Registration Statement Amendment Date and (ii)&nbsp;Company Periodic Report Date, the Company will
furnish or cause to be furnished to the Agent and to counsel to the Agent the written opinion and letter of each Company Counsel or other
counsel reasonably satisfactory to the Agent, dated the date of effectiveness of such amendment or the date of filing with the Commission
of such supplement or other document, as the case may be, in a form and substance reasonably satisfactory to the Agent and its counsel,
of the same tenor as the opinions and letters referred to in Section&nbsp;6(c)&nbsp;of this Agreement, but modified as necessary to relate
to the Registration Statement, the General Disclosure Package and the Prospectus as amended and supplemented, or to the document incorporated
by reference into the Prospectus, to the time of delivery of such opinion and letter or, in lieu of such opinion and letter, counsel last
furnishing such letter to the Agent shall furnish such Agent with a letter substantially to the effect that the Agent may rely on such
last opinion and letter to the same extent as though each were dated the date of such letter authorizing reliance (except that statements
in such last letter shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented to the time
of delivery of such letter authorizing reliance). As used in this paragraph, to the extent there shall be an Applicable Time on or following
the date referred to in clause (i)&nbsp;or (ii)&nbsp;above, promptly shall be deemed to be on or prior to the next succeeding Applicable
Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
commencement of the offering of Shares under this Agreement and each time the Shares are delivered to the Agent as principal on a Settlement
Date, and promptly after each (i)&nbsp;Registration Statement Amendment Date and (ii)&nbsp;Company Periodic Report Date, the Company will
cause Cherry Bekaert LLP, or other independent accountants reasonably satisfactory to the Agent, to furnish to the Agent a letter, dated
the date of effectiveness of such amendment or the date of filing of such supplement or other document with the Commission, as the case
may be, in form reasonably satisfactory to the Agent and its counsel, of the same tenor as the letter referred to in Section&nbsp;6(d)&nbsp;hereof,
but modified as necessary to relate to the Registration Statement, the General Disclosure Package and the Prospectus, as amended and supplemented,
or to the document incorporated by reference into the Prospectus, to the date of such letter. As used in this paragraph, to the extent
there shall be an Applicable Time on or following the date referred to in clause (i)&nbsp;or (ii)&nbsp;above, promptly shall be deemed
to be on or prior to the next succeeding Applicable Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company consents to Stifel Nicolaus trading in the Company&rsquo;s Common Stock for Stifel Nicolaus&rsquo; own account and for the account
of its clients at the same time as sales of Shares occur pursuant to this Agreement or any Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
to the knowledge of the Company, all filings required by Rule&nbsp;424 in connection with an offering of Shares shall not have been made
or the representations in Section&nbsp;1(a)&nbsp;shall not be true and correct on the applicable Settlement Date, the Company will offer
to any person who has agreed to purchase Shares from the Company as the result of an offer to purchase solicited by the Agent the right
to refuse to purchase and pay for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will cooperate timely with any reasonable due diligence review conducted by the Agent or its counsel from time to time in connection
with the transactions contemplated hereby or in any Terms Agreement, including, without limitation, and upon reasonable notice providing
information and making available documents and appropriate corporate officers, during regular business hours and at the Company&rsquo;s
principal offices, as the Agent may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will not, without (i)&nbsp;giving the Agent at least five business days&rsquo; prior written notice specifying the nature of the
proposed sale and the date of such proposed sale and (ii)&nbsp;the Agent suspending activity under this program for such period of time
as requested by the Company or as deemed appropriate by the Agent in light of the proposed sale, (A)&nbsp;offer, pledge, announce the
intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant for the sale of, lend or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock
or securities convertible into or exchangeable or exercisable for or repayable with Common Stock, or file any registration statement under
the 1933 Act with respect to any of the foregoing (other than a shelf registration statement under Rule&nbsp;415 under the 1933 Act, a
registration statement on Form&nbsp;S-8 or post-effective amendment to the Registration Statement) or (B)&nbsp;enter into any swap or
other agreement or any transaction that transfers in whole or in part, directly or indirectly, any of the economic consequence of ownership
of the Common Stock, or any securities convertible into or exchangeable or exercisable for or repayable with Common Stock, whether any
such swap or transaction described in clause (A)&nbsp;or (B)&nbsp;above is to be settled by delivery of Common Stock or such other securities,
in cash or otherwise. The foregoing sentence shall not apply to (y)&nbsp;the Shares to be offered and sold through the Agent pursuant
to this Agreement or any Terms Agreement and (z)&nbsp;equity incentive awards approved by the board of directors of the Company or the
compensation committee thereof or the issuance of Common Stock upon exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
immediately prior to the third anniversary (the &ldquo;<U>Renewal Deadline</U>&rdquo;) of the initial effective date of the Registration
Statement, any of the Shares remain unsold, the Company will, prior to the Renewal Deadline file, if it has not already done so and is
eligible to do so, an &ldquo;automatic shelf registration statement&rdquo; (as defined in Rule&nbsp;405 under the 1933 Act) relating to
the Shares, in a form satisfactory to the Agent. If the Company is not eligible to file an automatic shelf registration statement, the
Company will, prior to the Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Shares,
in a form satisfactory to the Agent, and will use its best efforts to cause such registration statement to be declared effective within
60 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of
the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration
Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4. <U>Free Writing Prospectus</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company represents and agrees that without the prior consent of the Agent, it has not made and will not make any offer relating to the
Shares that would constitute a &ldquo;free writing prospectus&rdquo; as defined in Rule&nbsp;405 under the 1933 Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Agent represents and agrees that, without the prior consent of the Company, it has not made and will not make any offer relating to the
Shares that would constitute a free writing prospectus required to be filed with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company has complied and will comply with the requirements of Rule&nbsp;433 under the 1933 Act applicable to any Issuer Free Writing Prospectus
(including any free writing prospectus identified in Section&nbsp;4(a)&nbsp;hereof), including timely filing with the Commission or retention
where required and legending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5. <U>Payment of Expenses</U>. The
Company covenants and agrees with the Agent that the Company will pay or cause to be paid the following: (i)&nbsp;the fees, disbursements
and expenses of the Company&rsquo;s counsel and accountants in connection with the registration of the Shares under the 1933 Act and all
other expenses in connection with the preparation, printing and filing of the Registration Statement, the Basic Prospectus, Prospectus
Supplement, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering
of copies thereof to the Agent; (ii)&nbsp;the cost of printing or producing this Agreement or any Terms Agreement, any Blue Sky and Legal
Investment Memoranda, closing documents (including any compilations thereof) and any other documents in connection with the offering,
purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification of the Shares for offering and
sale under state securities laws as provided in Section&nbsp;3(b)&nbsp;hereof, including the reasonable fees and disbursements of counsel
for the Agent in connection with such qualification and in connection with the Blue Sky and Legal Investment Surveys; (iv)&nbsp;any filing
fees incident to, and the reasonable fees and disbursements of counsel for the Agent in connection with, any required review by the Financial
Industry Regulatory Authority,&nbsp;Inc. (&ldquo;<U>FINRA</U>&rdquo;) of the terms of the sale of the Shares; (v)&nbsp;all fees and expenses
in connection with listing or quoting the Shares on Nasdaq; (vi)&nbsp;the cost of preparing the Shares; (vii)&nbsp;the costs and charges
of any transfer agent or registrar or any dividend distribution agent; (viii)&nbsp;the reasonable fees and disbursements of counsel to
the Agent in an aggregate amount not to exceed (A)&nbsp;$75,000 arising out of executing this Agreement (which amount shall include all
fees and disbursements of such counsel described in clauses (iii)&nbsp;and (iv)&nbsp;above) and (B)&nbsp;$10,000 in connection with each
Company Periodic Report Date on which the Company is required to provide a certificate pursuant to Section&nbsp;6(f); and (ix)&nbsp;all
other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in
this Section. It is understood, however, that, except as provided in this Section, and Section&nbsp;7 hereof, the Agent will pay all of
its own costs and expenses, including the fees of its counsel, transfer taxes on resale of any of the Shares by it, and any advertising
expenses connected with any offers it may make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6. <U>Conditions of Agent&rsquo;s
Obligations</U>. The obligations of the Agent hereunder shall be subject, in its discretion, to the condition that all representations
and warranties and other statements of the Company herein or in certificates of any officer of the Company delivered pursuant to the provisions
hereof are true and correct as of the time of the execution of this Agreement, the date of any executed Terms Agreement and as of each
Registration Statement Amendment Date, Company Periodic Report Date, Applicable Time and Settlement Date, to the condition that the Company
shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Prospectus Supplement shall have been filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the 1933 Act on or prior to the
date hereof and in accordance with Section&nbsp;3(a)&nbsp;hereof, any other material required to be filed by the Company pursuant to Rule&nbsp;433(d)&nbsp;under
the 1933 Act shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule&nbsp;433;
no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding
for that purpose shall have been initiated or threatened by the Commission and no notice of objection of the Commission to the use of
the form of the Registration Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the 1933 Act
shall have been received; no stop order suspending or preventing the use of the Prospectus or any Issuer Free Writing Prospectus shall
have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have
been complied with to the reasonable satisfaction of the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
every date specified in Section&nbsp;3(k)&nbsp;hereof and on such other dates as reasonably requested by Agent, Duane Morris LLP, counsel
for the Agent, shall have furnished to the Agent such written opinion or opinions, dated as of such date, with respect to such matters
as the Agent may reasonably request, and such counsel shall have received such papers and information as they may reasonably request to
enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
every date specified in Section&nbsp;3(k)&nbsp;hereof and on such other dates as reasonably requested by Agent, Bass, Berry&nbsp;&amp;
Sims PLC, counsel for the Company, shall have furnished to the Agent written opinion or opinions, dated as of such date, in form and substance
reasonably satisfactory to the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
the dates specified in Section&nbsp;3(l)&nbsp;hereof and on such other dates as reasonably requested by Agent, the independent accountants
of the Company who have certified the financial statements of the Company and its Subsidiaries included or incorporated by reference in
the Registration Statement, the General Disclosure Package and the Prospectus shall have furnished to the Agent a letter dated as of the
date of delivery thereof and addressed to the Agent in form and substance reasonably satisfactory to the Agent and its counsel, containing
statements and information of the type ordinarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect
to the financial statements of the Company and its Subsidiaries included or incorporated by reference in the Registration Statement, the
General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Prior
to commencement of the offering of Shares under this Agreement, the Agent shall have received a certificate, signed on behalf of the Company
by its corporate Secretary, in form and substance satisfactory to the Agent and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;Upon
commencement of the offering of Shares under this Agreement and on such other dates as reasonably requested by Agent, the Company will
furnish or cause to be furnished promptly to the Agent a certificate of an officer in a form satisfactory to the Agent stating the minimum
price for the sale of such Shares pursuant to this Agreement and the maximum number of Shares that may be issued and sold pursuant to
this Agreement or, alternatively, maximum gross proceeds from such sales, as authorized from time to time by the Company&rsquo;s board
of directors or a duly authorized committee thereof or, in connection with any amendment, revision or modification of such minimum price
or maximum Share number or amount, a new certificate with respect thereto and (ii)&nbsp;on each date specified in Section&nbsp;3(j)&nbsp;and
on such other dates as reasonably requested by Agent, the Agent shall have received a certificate of executive officers of the Company,
one of whom shall be the Chief Financial Officer, Chief Accounting Officer, Treasurer, or Executive Vice President in the area of capital
markets and investments, dated as of the date thereof, to the effect that (A)&nbsp;there has been no Material Adverse Effect since the
date as of which information is given in the General Disclosure Package and the Prospectus as then amended or supplemented, (B)&nbsp;the
representations and warranties in Section&nbsp;1 hereof are true and correct as of such date and (C)&nbsp;the Company has complied with
all of the agreements entered into in connection with the transaction contemplated herein and satisfied all conditions on its part to
be performed or satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Since
the date of the latest audited financial statements then included or incorporated by reference in the General Disclosure Package and the
Prospectus, no Material Adverse Effect shall have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall have complied with the provisions of Section&nbsp;3(c)&nbsp;hereof with respect to the timely furnishing of prospectuses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
such dates as reasonably requested by the Agent, the Company shall have conducted due diligence sessions, in form and substance satisfactory
to the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
filings with the Commission required by Rule&nbsp;424 under the 1933 Act to have been filed by each Applicable Time or related Settlement
Date shall have been made within the applicable time period prescribed for such filing by Rule&nbsp;424 (without reliance on Rule&nbsp;424(b)(8)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Shares shall have received approval for listing or quotation on Nasdaq prior to the first Settlement Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Prior
to any Settlement Date, the Company shall have furnished to the Agent such further information, documents or certificates as the Agent
may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7. <U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will indemnify and hold harmless the Agent against any losses, claims, damages or liabilities, joint or several, to which the
Agent may become subject, under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement, the Basic Prospectus, the Prospectus Supplement or the Prospectus or any amendment or supplement thereto, any Issuer Free Writing
Prospectus or any &ldquo;issuer information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under the 1933 Act,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, and will reimburse the Agent for any legal or other expenses reasonably incurred by the
Agent in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the
Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon
an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Basic Prospectus,
the Prospectus Supplement or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance
upon and in strict conformity with written information furnished to the Company by the Agent expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Agent will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become
subject, under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise
out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the
Basic Prospectus, the Prospectus Supplement or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged
untrue statement or omission or alleged omission was made in the Registration Statement, the Basic Prospectus, the Prospectus Supplement
or the Prospectus, or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in strict
conformity with written information furnished to the Company by the Agent expressly for use therein; and will reimburse the Company for
any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim
as such expenses are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Promptly
after receipt by an indemnified party under subsection (a)&nbsp;or (b)&nbsp;above of notice of the commencement of any action, such indemnified
party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying
party in writing of the commencement thereof; but the omission so to notify the indemnifying party shall not relieve it from any liability
which it may have to any indemnified party otherwise than under such subsection except and then only to the extent such indemnifying party
is materially prejudiced thereby. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying
party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish,
jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified
party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from
the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be
liable to such indemnified party under this Section&nbsp;7 for any legal expenses of other counsel or any other expenses, in each case
subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation.
No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent
to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution
may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement,
compromise or judgment (i)&nbsp;includes an unconditional release of the indemnified party from all liability arising out of such action
or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of
any indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the indemnification provided for in this Section&nbsp;7 is unavailable to hold harmless an indemnified party under subsection (a)&nbsp;or
(b)&nbsp;above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages
or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company
on the one hand and the Agent on the other from the offering of the Shares to which such loss, claim, damage or liability (or action in
respect thereof) relates. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law,
then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate
to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Agent on the other in connection
with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well
as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Agent on the other
shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company
bear to the total commissions received by the Agent. The relative fault shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Company on the one hand or the Agent on the other and the parties&rsquo; relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable
if contribution pursuant to this subsection (d)&nbsp;were determined by pro rata allocation or by any other method of allocation which
does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified
party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d)&nbsp;shall
be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending
any such action or claim. Notwithstanding the provisions of this subsection (d), the Agent shall not be required to contribute any amount
in excess of the amount by which the total compensation received by the Agent with respect to sales of the Shares sold by it to the public
exceeds the amount of any damages which the Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement
or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the
1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
obligations of the Company under this Section&nbsp;7 shall be in addition to any liability which the Company may otherwise have and shall
extend, upon the same terms and conditions, to the directors, officers, employees, attorneys and agents of the Agent and to each person,
if any, who controls the Agent within the meaning of the 1933 Act and each broker dealer affiliate of the Agent; and the obligations of
the Agent under this Section&nbsp;7 shall be in addition to any liability which the Agent may otherwise have and shall extend, upon the
same terms and conditions, to each director, officer, employee, attorney and agent of the Company and to each person, if any, who controls
the Company within the meaning of the 1933 Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8. <U>Representations, Warranties
and Agreements to Survive Delivery</U>. The respective indemnities, agreements, representations, warranties and other statements of the
Company and the Agent, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall
remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of
the Agent or any controlling person of the Agent, or the Company, or any officer or director or controlling person of the Company, and
shall survive delivery of and payment for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9. <U>No Advisory or Fiduciary Relationship</U>.
The Company acknowledges and agrees that (i)&nbsp;the Agent is acting solely in the capacity of an arm&rsquo;s length contractual counterparty
to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of such
offering) and (ii)&nbsp;the Agent has not assumed an advisory or fiduciary responsibility in favor of the Company with respect to the
offering contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the
Company on other matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement and (iii)&nbsp;the
Company has consulted its own legal and financial advisors to the extent it deemed appropriate. The Company agrees that it will not claim
that the Agent has rendered advisory services of any nature or respect, or owe a fiduciary or similar duty to the Company, in connection
with such transaction or the process leading thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10. <U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall have the right, by giving written notice as hereinafter specified, to terminate this Agreement in its sole discretion at
any time. Any such termination shall be without liability of any party to any other party, except that (i)&nbsp;with respect to any pending
sale through the Agent for the Company, the obligations of the Company, including in respect of compensation of the Agent, shall remain
in full force and effect notwithstanding such termination; and (ii)&nbsp;the provisions of Section&nbsp;1, Section&nbsp;5, Section&nbsp;7,
Section&nbsp;8, Section&nbsp;14 and Section&nbsp;15 of this Agreement shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Agent shall have the right, by giving written notice as hereinafter specified, to terminate this Agreement in its sole discretion at any
time. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;1, Section&nbsp;5,
Section&nbsp;7, Section&nbsp;8, Section&nbsp;14 and Section&nbsp;15 of this Agreement shall remain in full force and effect notwithstanding
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
earlier terminated pursuant to this Section&nbsp;10, this Agreement shall automatically terminate upon the issuance and sale of all of
the Shares by Stifel Nicolaus on the terms and subject to the conditions set forth herein except any termination pursuant to this clause
(c)&nbsp;shall in all cases be deemed to provide that Section&nbsp;1, Section&nbsp;5(b), Section&nbsp;7, Section&nbsp;8, Section&nbsp;14
and Section&nbsp;15 of this Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement shall remain in full force and effect until and unless terminated pursuant to Section&nbsp;10(a), (b)&nbsp;or (c)&nbsp;above
or otherwise by mutual agreement of the parties; <U>provided</U> that any such termination by mutual agreement or pursuant to this clause
(c)&nbsp;shall in all cases be deemed to provide that Section&nbsp;1, Section&nbsp;5, Section&nbsp;7, Section&nbsp;8, Section&nbsp;14
and Section&nbsp;15 of this Agreement shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
termination of this Agreement shall be effective on the date specified in such notice of termination; <U>provided</U> that such termination
shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall settle in accordance with the
provisions of Section&nbsp;2(h)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the case of any purchase by the Agent pursuant to a Terms Agreement, the Agent may terminate this Agreement, at any time at or prior to
the Settlement Date (i)&nbsp;if there has been, since the time of execution of this Agreement or since the respective dates as of which
information is given in the General Disclosure Package or the Prospectus, any Material Adverse Effect, or (ii)&nbsp;if there has occurred
any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities
or escalation thereof or other calamity or crisis or any change or development involving a prospective change in national or international
political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Agent, impracticable
or inadvisable to market the Shares or to enforce contracts for the sale of Shares, or (iii)&nbsp;if trading in any securities of the
Company has been suspended or materially limited by the Commission or Nasdaq, or if trading generally on the American Stock Exchange or
the NYSE or Nasdaq has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges
for prices have been required, by any of said exchanges or by such system or by order of the Commission, FINRA or any other </FONT>Governmental
Entity, or (iv)&nbsp;a material disruption has occurred in commercial banking or securities settlement or clearance services in the United
States, or (v)&nbsp;if a banking moratorium has been declared by either Federal or New York authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11. <U>Notices</U>. All statements,
requests, notices and agreements hereunder shall be in writing, and if to Stifel Nicolaus shall be delivered or sent by mail, telex or
facsimile transmission to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated<BR>
One South Street, 15<SUP>th</SUP> Floor<BR>
Baltimore, Maryland 21202<BR>
Fax No.&nbsp; (443) 224-1273<BR>
Attention: Syndicate Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Duane Morris LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">1540 Broadway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: James T. Seery</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">E-mail: jtseery@duanemorris.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">and if to the Company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ClearPoint Neuro,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">120 S. Sierra Ave., Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Solana Beach, California 92075</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Danilo D&rsquo;Alessandro</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">E-mail: ddalessandro@clearpointneuro.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Bass, Berry&nbsp;&amp; Sims PLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Tower at Peabody Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">100 Peabody Place, Suite&nbsp;1300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Memphis, Tennessee 38103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Richard Mattern</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: rmattern@bassberry.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any such statements, requests, notices or agreements
shall take effect upon receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12. <U>Parties</U>. This Agreement
shall be binding upon, and inure solely to the benefit of, the Agent and the Company and, to the extent provided in Sections 7 and 8 hereof,
the officers, directors, employees, attorneys and agents of the Company and the Agent and each person who controls the Company or the
Agent, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right
under or by virtue of this Agreement. No purchaser of Shares through the Agent shall be deemed a successor or assign by reason merely
of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;13. <U>Time of the Essence</U>. Time
shall be of the essence of this Agreement. As used herein, the term &ldquo;business day&rdquo; shall mean any day when the Commission&rsquo;s
office in Washington, D.C. is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14. <U>Waiver of Jury Trial</U>. The
Company and the Agent hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to jury trial by
jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;15. <U>Governing Law</U>. THIS AGREEMENT
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO ITS PRINCIPLES OF CONFLICTS
OF LAW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;16. <U>Counterparts</U>. This Agreement
and any Terms Agreement may be executed by any one or more of the parties hereto and thereto in any number of counterparts, each of which
shall be deemed to be an original, but all such respective counterparts shall together constitute one and the same instrument. This Agreement
and any Terms Agreement may be delivered by any party by facsimile or other electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;17. <U>Severability</U>. The invalidity
or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other
Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid
or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid
and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the foregoing is in accordance with your understanding of our agreement,
please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding
agreement between the Agent and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CLEARPOINT NEURO,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Danilo D&rsquo;Alessandro</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name: Danilo D&rsquo;Alessandro</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title: &nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Accepted as of the date hereof:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>STIFEL, NICOLAUS&nbsp;&amp; COMPANY,&nbsp;INCORPORATED</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Nicholas Oust&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name: Nicholas Oust</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Title: &nbsp;&nbsp;Managing Director</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><I>Signature
Page&nbsp;to Sales Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro (Canada) Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro UK Ltd</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro Germany GmbH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro Italy, S.r.l.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notice Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>The Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joseph M. Burnett&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;jburnett@clearpointneuro.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Danilo D&rsquo;Alessandro&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ddalessandro@clearpointneuro.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stifel Nicolaus</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Covatta&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;dcovatta@stifel.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark White&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;whitem@stifel.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Annex 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CLEARPOINT NEURO,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock<BR>
($0.01 par value per share)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STIFEL, NICOLAUS&nbsp;&amp; COMPANY,&nbsp;INCORPORATED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One South Street, 15<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baltimore, MD 21202</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Syndicate Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ClearPoint Neuro,&nbsp;Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), proposes, subject to the terms and conditions stated herein and in the At-the-Market Equity Offering
Sales Agreement, dated November&nbsp;7, 2024 (the &ldquo;<U>Sales Agreement</U>&rdquo;), between the Company and Stifel, Nicolaus&nbsp;&amp;
Company,&nbsp;Incorporated (the &ldquo;<U>Agent</U>&rdquo;), to issue and sell to the Agent the securities specified in the Schedule hereto
(the &ldquo;<U>Purchased Securities</U>&rdquo;) [, and solely for the purpose of covering over-allotments, to grant to the Agent the option
to purchase the additional securities specified in the Schedule hereto (the &ldquo;<U>Additional Securities</U>&rdquo;)]*.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[The Agent shall have the right to purchase from
the Company all or a portion of the Additional Securities as may be necessary to cover over-allotments made in connection with the offering
of the Purchased Securities, at the same purchase price per share to be paid by the Agent to the Company for the Purchased Securities.
This option may be exercised by the Agent at any time (but not more than once) on or before the thirtieth day following the date hereof,
by written notice to the Company. Such notice shall set forth the aggregate number of shares of Additional Securities as to which the
option is being exercised, and the date and time when the Additional Securities are to be delivered (such date and time being herein referred
to as the &ldquo;<U>Option Closing Date</U>&rdquo;); provided, however, that the Option Closing Date shall not be earlier than the Time
of Delivery (as set forth in the Schedule hereto) nor earlier than the second business day after the date on which the option shall have
been exercised nor later than the fifth business day after the date on which the option shall have been exercised. Payment of the purchase
price for the Additional Securities shall be made at the Option Closing Date in the same manner and at the same office as the payment
for the Purchased Securities.]*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the provisions of the Sales Agreement not
specifically related to the solicitation by the Agent, as agent of the Company, of offers to purchase securities is incorporated herein
by reference in its entirety, and shall be deemed to be part of this Terms Agreement to the same extent as if such provisions had been
set forth in full herein. Each of the representations and warranties set forth therein shall be deemed to have been made at and as of
the date of this Terms Agreement [and] [,] the Applicable Time [and any Option Closing Date]*, except that each representation and warranty
in Section&nbsp;1 of the Sales Agreement which makes reference to the Prospectus (as therein defined) shall be deemed to be a representation
and warranty as of the date of the Sales Agreement in relation to the Prospectus, and also a representation and warranty as of the date
of this Terms Agreement [and] [,] the Settlement Date [and any Option Closing Date]* in relation to the Prospectus as amended and supplemented
to relate to the Purchased Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An amendment to the Registration Statement (as
defined in the Sales Agreement), or a supplement to the Prospectus, as the case may be, relating to the Purchased Securities [and the
Additional Securities]*, in the form heretofore delivered to the Agent is now proposed to be filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the terms and conditions set forth herein
and in the Sales Agreement which are incorporated herein by reference, the Company agrees to issue and sell to the Agent and the latter
agrees to purchase from the Company the number of shares of the Purchased Securities at the time and place and at the purchase price set
forth in the Schedule hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding
of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between the Agent and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CLEARPOINT NEURO,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Accepted as of the date hereof:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">STIFEL, NICOLAUS&nbsp;&amp; COMPANY,&nbsp;INCORPORATED</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Name:</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Title:</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Include
only if the Agent has an over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm2427351d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT><B>Exhibit&nbsp;5.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2427351d2_ex5-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Tower at Peabody Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">100 Peabody Place, Suite&nbsp;1300<BR>
Memphis, Tennessee 38103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(901) 543-5900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November&nbsp;7, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">120 S. Sierra Ave., Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Solana Beach, CA 92075</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Re:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">ClearPoint
Neuro,&nbsp;Inc.&rsquo;s At-The-Market Offering Program</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have acted as counsel to ClearPoint Neuro,&nbsp;Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection
with a Registration Statement on Form&nbsp;S-3, Registration No.&nbsp;333-275476 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;),
filed by the Company with the U.S. Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) pursuant to the Securities
Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and the related Prospectus Supplement filed with the Commission
on November&nbsp;7, 2024 (the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;), relating to the offering of up to $50,000,000 of shares
(the &ldquo;<B><I>Shares</I></B>&rdquo;) of the Company&rsquo;s common stock, par value $0.01 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;),
which shares are to be offered and sold by the Company from time to time in accordance with the terms of that certain At-The-Market Equity
Offering Sales Agreement, dated as of November&nbsp;7, 2024 (the &ldquo;<B><I>Sales Agreement</I></B>&rdquo;) entered into by the Company
and Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated (the &ldquo;<B><I>Agent</I></B>&rdquo;). This opinion is being furnished in
connection with the requirements of Item&nbsp;601(b)(5)&nbsp;of Regulation S-K under the Securities Act, and no opinion is expressed herein
as to any matter pertaining to the contents of the Registration Statement or the Prospectus Supplement, other than as expressly stated
herein with respect to the issuance of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus Supplement, the Sales Agreement,
the Company&rsquo;s Amended and Restated Certificate of Incorporation, as amended from time to time, the Company&rsquo;s Fourth Amended
and Restated Bylaws, that certain Opinion Certificate dated as of the date hereof and delivered by Danilo D&rsquo;Alessandro, Chief Financial
Officer of the Company, and originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda
and other instruments as in our judgment are necessary or appropriate to enable us to render the opinions expressed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
our aforesaid examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the accuracy and
completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents
of all documents submitted to us as certified, telecopied, photostatic, or reproduced copies. We have also assumed the accuracy, completeness
and authenticity of the foregoing certifications of officers and statements of fact, on which we are relying, and have made no independent
investigations thereof. This opinion letter is given, and all statements herein are made, in the context of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
upon and subject to the foregoing and the other assumptions and qualifications set forth herein, it is our opinion that, upon issuance,
delivery and payment therefor in the manner contemplated by the Registration Statement, the Prospectus Supplement, the Sales Agreement
(and any related Terms Agreement (as defined in the Sales Agreement)) and resolutions of the board of directors of the Company or a duly
authorized committee thereof, the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
opinion also is subject to the following qualifications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Our opinions as set forth herein are limited in all respects to the federal laws of the United States
of America and, to the extent applicable, the General Corporation Law of the State of Delaware. No opinion is given regarding the laws
of any other jurisdiction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">We express no opinion with respect to the registration or qualification of the Securities under any state
securities or &ldquo;Blue Sky&rdquo; laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">This letter is strictly limited to those matters expressly addressed herein. We express no opinion as
to any matter not specifically stated to be and numbered above as an opinion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">This letter is rendered as of the date hereof and we assume no responsibility to update this letter for
any changes in applicable law occurring after the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Our opinion rendered in the above paragraph is subject to the following exceptions, limitations and qualifications:
(i)&nbsp;the effect of bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer and other similar
laws now or hereafter in effect relating to or affecting creditors&rsquo; rights and remedies generally; and (ii)&nbsp;the effect of general
principles of equity (including, without limitation, laches and estoppel as equitable defenses, concepts of materiality, reasonableness,
good faith and fair dealing, matters of public policy, the possible unavailability of specific performance, injunctive relief and other
equitable remedies, the discretion of the court before which a proceeding is brought, and considerations of impracticability or impossibility
of performance and defenses based upon unconscionability), regardless of whether considered in a proceeding at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Securities Act. We consent to your filing this opinion as an exhibit to the Company&rsquo;s
Current Report on Form&nbsp;8-K, to be filed November&nbsp;7, 2024 and to reference this firm under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus Supplement constituting a part of the Registration Statement. In giving such consent, we do not thereby admit that we
are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations
of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Bass, Berry&nbsp;&amp; Sims, PLC</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clpt-20241107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaKDWbOdzZR+2YkxtmBwbekanyQmVrO+pCSCXQP2AdoG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:clpt="http://clearpointneuro.com/20241107" elementFormDefault="qualified" targetNamespace="http://clearpointneuro.com/20241107">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://clearpointneuro.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="clpt-20241107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="clpt-20241107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>clpt-20241107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>clpt-20241107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://clearpointneuro.com/role/Cover" xlink:href="clpt-20241107.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://clearpointneuro.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2427351d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2427351d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  8 /L# 2(  A$! Q$!_\0
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M3P7)>^+-<T<3>'(-)UAHIEAF\0Z]<6^B)]I*1JS"1/F,:S?L[7\B?_!UG;>
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M;W=B00U?Q*_\$'_VR_\ @DY^Q1X<^"^F:;\=_P!J'6?VE/V@?A'\!?A/\1_
M'CKP[XP\3?#7PA\4=:E\/?VWI'@93#+#H6@P?$37#H$$A^1?"\,#%"@)']EG
M[8T8D_9'_:HBCP"W[-WQT0#MN;X9>(L#]10!_+5\./\ @X^_X* ^._V;8?VV
ME_X)"^(O$/['%AI?B3Q+XD^+_A3XVZ'Y=AX5\#:OK?A_QWK"M<0MKT=OX6\0
M:!KL,C-X14;=&DD5E!$R?U2_LO\ Q^\ ?M4_L_\ P?\ VDOA9)//X!^-G@7P
MW\0_#KZC:+I^J66G^(M-CF&DZQ%L$B:YX?D$F@7J J%GMW0/,B"5O\T71?V:
M/V]?A]_P;^_ ']J/PI^UG^T!JW[&7COXB>.? /[1?['GA8?V?I'@7X.:S\?_
M (@> _&VMZ/&Z,+C_A*?$^B[I(I8A"UQ\0 LG[AI8W_TC_V+/!_P6^'O[)O[
M-OA#]G1TN?@+HWP4^&=G\(;\D>;JG@+_ (1#0O\ A']:UDSE6DU[Q%!(MQ=2
M9<-<32;-AWQ$ _#3]I;_ (+8_MM^$O\ @H9^U+^P7^QU_P $XQ^UIJG[,ME\
M,-9\0Z_HWQ5TOPMJD>D?%+X9> /'4>K:OHNNI'&B+XA\<?\ ",1BVD.U5)D9
M9&^;] ?^"57_  5#TO\ X*0^'OCMHWB?X/>)?V=_VAOV6?B3'\)?V@?@IXKU
M:#7Y/"/B>=M<.DZCI&NK'#'-!<2^'?&%HT;6YD$F@2,MQ+"\9C_FX^)O[)G[
M9/[37_!?;_@M4O[&G[5_Q+_9,^)'@SX)_LX^*-'U;P5OT[3_ (LZJW[/GP>3
M0/!6OZR5PN@#Q''N=UR-K9<J(R%_1C_@U-\/^!+G]D7]HKXHZ_-XZU']M7XB
M_M/^/+;]N75_B@3_ ,)K?_%+PUK6NW/AW;EP?[#31/&>KS@L&V^,-8\7#* #
M(!^CB_\ !3O5O '_  56U+_@FY^T5\*=/^&FC?$_X:-\3/V0_CM;:^\OAOXT
MKHJ^;XD\$ZQ#(%'A[Q3H(BUQ%A>8+YOALRM%GQ;X16XM_P#!/#_@IAK/_!17
MXZ?M<VWPK^$MK9_L>_L\^.3\)_AU^T=<ZQ-CXZ^/M%E4>)4\%Z&Z1Q'PWX75
M%NG\0PL4GA\1>& O[[SDC^#O^#JOX#^$?%G_  2Y\5_M(65GJ.F?'3]D[XC?
M##QM\&/&OA9FTSQ%H#>/OB?X#^%7CC2WU6!()DT.[\/:_P#:IOE"->>'O#F\
M$*6E_7K_ ()H_LZ_#']EC]@S]EOX*?"GP_;>'_"V@_!KP%KMU$Z(-1U;Q3XU
MT.S\2>-=>UIL0L^M^)?$VLZW<S.S2E9IFB$FV.., 'U'XX\7Z9\//!OB3QEJ
M5MJ%S8>'='U#6KJSTFR2\U75$TF)A)8Z;I48<3W,V"JQ)R2?G8 [TY;X(_%>
MV^.7PG\*_$:PT36_"$WB?1EN9O#NO6:6FM>'KUT_>0S6[*@VJ5;#@L/*<-@.
M'#?*W[:7[,>O_%.SUCXB:'\2O'NECPS\+/'&B#P#X=NP=.O3K.@:E"FK:;I)
M/[SQ3^]CC@E;F9%11ND4Y\4_X)Z_LQ:YX?T/X3?&^_\ BI\18M/_ .%;:MHT
M7P[U1SI>GZXNN>+O'6OMK.MZ)M*G1$C\01R^"X]ZM';,DY^5HQ)^BX7A[A&7
M 3SI\51>>1QD91I/"U?W<U&HX\+M<KC.=1J$HXEMTHPC[)M6=_Q+%\9<=87Q
M-RSAG"\'SED,\+)5%]8X7C%4_P#6:-.7%ZK<ZJI0IMK_ %5456;?MK\]C[S_
M &O?VE?!'['7[,WQP_:D^(\>HWO@OX(^!-2\>:QIFD-&FJ:TVD '1]%T@L71
M;GQ/KLVD>'87F'DA[@22)(F\M^&'[&W_  6A_P""A'[0GQ0_9PO_ (E?\$G_
M !YX0_90_:XUK2V^#_QU\ _$G2_&P\,^&/$,;Z]HOC3QX$'D?\(X?#Y62<S+
MX/SO>2)/.9?"$?[&_P#!0WQ'\)/"?[#_ .TYJWQW^%?BWXT?"*+X0^*['Q]\
M*? FCW'B+Q1XV\.:SMTA]%T+2" OVF22XAG\\N&\,H#=H<0AC_!'\)/C/\&/
MV>OVI/V+X?\ @AA^U3^V5XRU_P"(?[0/@/P?\8/V)?BAI6NW_@?PG\+=;UHK
MKR:R^O*8E&UQX?F,RQ@1V[>-XYT<A9OSH_;3_1P^+'CH_#/X4?%#XDPV*ZE)
M\._A[XW\:1:>N%_M)O!V@:WK::6A&"&E;2Q""N&&_(QR1\A?\$N_VU[S_@H;
M^PE\"?VQ]0\%6?P\N_C):>/KNX\'66K'5=.T,^!_BAXZ^'GRZL84DD25_!1E
M9Y%#*9<21KT'T+^U<1)^RS^TO#'U/[/WQC4?\"^&WB )^/S#\*_)_P#X-FK6
M>S_X(>_L,V]Y#-;W%MI/QY#V]P &5O\ AJ#XZ8!';<C[L$ A O &* .A_;!_
MX+'>#OV-?^"I'['/_!/CXB^"=.7P/^U;X&TG71\9KKQ MF_@CQ5XP\8^// G
M@?1IM'=7BDT7Q#XJ\+Z+X=%R\D!AEUU2"\<,K&3]L'_@L3X2_9F_X*=?L5?\
M$V_#W@;2_'/C3]IR]TN7XC>))_$CZ<?A5I7B+6GT?P-LT@(R:WKGB0:/XB=8
MKB6VVHGAXH9=X6OPH_X. /V+==_;P_X+._ /X!>%O[4M/&^J?\$N/B=XQ^$.
MO6)-B=.^,?PN\<?'CQWX$6765(\I?$GB+1]"\,28;,<.N&<$$X'YU_LX?!O]
MI'QQ^WA_P1B_X*4?M7KXBN/VC/V]?VYOB5>Z_;ZS::JG_"+_  ?_ &<_!WP<
M^%'PMMO*\V1M"E\22/XTEPXC62U3PI<!0?,1 #_0\_:$^-?@W]G#X&_&']H+
MX@K>GP'\#?AKXZ^*_C-])LGO]1_X1GP+H&M>(M931HE*B76?(TML0LV-Y"G!
M/F+_ #I?LG_\%T/V^?VC?%OP,^)-S_P23^)$7[%/[3?CC1_!GPK^,7P_^(^B
M^-/$NBZ=K?B$:'-XS\:Z%%!Y:Z%X9.D:_+=-(?!,3I"=C"81*_\ 0)^UMK/P
M[T']E[]H35_BQX#UOXI?"ZR^#OQ%'Q%^&7A71/\ A*/$?C_P.?!^L+XB\(:/
MH@ ;69_$7A]KJV6V\P,RO("_RL(_\Y.Z^-G[/'[.'BSX!^,/^"$/[1_[:]A^
MT=XL^-7@;0]7_8#^(FD:YJ?@;3],UW60VNZ+XW &T^'CXD_L/PFRR*R%'.3&
MS+)& ?Z@M%?.'C3]HSP/X!^*$/PM\1V>NVVIS>!;+Q]_PD,.E&7PQ9:7)K6M
MZ&-&DUA9 %UUCH.LR)!E3Y6PCR]Y%>F^!?'EMXX\(Z!XMTW1]3M['7K"._MH
M70%XXY'=<,5('5"> .".] '.O\ ?@9<WL^I7/P7^%%UJUS<_;;S5KOX<>#FU
M.[U!55#J4L[Z&TDEP2,^>QW%B23USZG;6L%G;0V5C%#;6]M;K:VUO;A0MH N
M%4 8 10J]LY&3G)-%% &!IO@_P )Z1K&L^(]'\+^'=(UWQ.T3^(==TK0M(L-
M6UHJN5;6]6B@6XUDAL%6F:9EQU!QE$\'>#XO$\_C*+PKX>M_%]Q8KI5WXP@T
M;2QXCN].0,1I#Z['&-=>-#AQ"TVS* A<A<%% %GQ)X=\.^+]'NO#_BK0-'\2
MZ)J2!;K1O$&DZ=JFE7QZ$3Z3JZ2PR$9)42QDACN4Y.3A> OAC\-?AC8SZ7\-
MOAYX+\ :=='[3<VW@GPIHOAC3KUFZ,8="MX$9N 5#JY YC4[J** .QO;*RU6
MTGL+^VM]0L+NV^SW5K=6J7MC=QMU5XV#K(H.00X(Z' 901YYX+^#/P?^&MQ?
MWOPY^%OPY^'VH:EL_M>\\#^!?"7AK4-38KD+JTOA[0K9IP0"<N74]1UHHH ]
M7KA/%G@'P/XZM;>T\;>"O"GC:WT^X%S9VGBKP]I/B..R?!(D1-=254<\_.H'
M &0P48** $\)?#?X>^!5N1X)\ ^#O!7VSB[_ .$4\,Z)X<%Y@'D_V';P$X/.
M&W-G&.>1O:YH6B^(]*O]%\0Z5I^LZ3J,0M;S2]5LTU+3;R,?,RR:;-YD3KG)
M(QN^4.6XW$HH \RM/V>_@'8W5O?:=\$?A!IEY;7 N[2]L_AQX.L-0M;\@_O(
MI(] 61)"IXD#;\8(1L*P]9O;*VOK6>SOX8;FSN+4VMS:72J;*Y20#*LK!L*>
M5/RG(( &5!!10!R4'@#X>VGA,>!K;P-X4@\%#Y1X+@\-Z-'X8_U@U4PG0Q"-
M!"F4>:08/*\P!@X &.AT31=*T#2K#1-$TW3M(TC3+3['I>DZ99C3M/L;!5 2
M*/2X_+CC5&&-JH,L[$[6=B2B@#,L/!_A32M<U;Q/I_A;P[IWB/Q L-KKNO6>
M@:1I_B#6D0 JNLZO#$DNL*"JE%E>0)C:GW"HAT#P9X/\*W&KZAX7\*>'?#=_
MXEN_[3\07>B:)I.EZCKNI!&0:OK<FBQPMK4S9^9IV=_F?D!B%** -#Q'X=\.
M^+]'FT#Q5X;T?Q/H=XH%UHWB#1]-U32KX@$%9M*UA)87V[B5\R/*Y)#'.3K6
MUK!9VT-E8Q0VUO;6ZVMM;VX4+: +A5 & $4*O;.1DYR3110!HU1@MX+>*&"&
M*"""W ^S6]OM   .,#"@#DG"YZDEC110!/-%#/&898A-#-PZGE2" 03R#CCL
M>*\H\+_ WX,>"-9N/%'@;X2?"_PCXGU)"+SQ-X9\!^#_  ]XAO.V;C6=$T.*
MXF!7KN=@>"3D444 >FWEE;WMK-97L,%W;7=LUM<VUP!MO%*X*MUR""V>,@MG
M@@$9/A_P]X<\*:/#H'A70-&\-:+IJ[;31O#^DZ?INE6).,+!I.CK%%'D#)5(
MUW8R>F044 5G\(>%+CQ#9^,KCP_X?N/%VGVCZ3:^*+C2=+D\1V>GR,'DTI-8
M"FYC1G/,,<HA^9ODRY=H;CP'X'NYO#-S?>$/"UQ/X-;[7X5N;CPYI6?"S; I
M.@%H=^A,$7AK4Q8VGYB4 4HH [:O(-#^!WP9\,^)YO''ASX0?##PSXYNE+W7
MBW0/ 7A'3?$MX>ZRZ_;:%'KT@&,[3(!V&XT44 >B:CI&EZDO_$STS3]0&;4@
M7=FE]RLAP<2(W"DY5AQU9P1Q4=AH>FZ;9V]CIVG:386-M&([:SM-(2&WMXP2
31'%&C(BKDDD!5RQ)QDFBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45487485124528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CLEARPOINT NEURO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001285550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2394628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">120 S. Sierra Ave., Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Solana Beach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">287-9109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ 3(AG60=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" !,B&=9-8X+M>X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " !,B&=9F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $R(9UFA
MPJ#56 0  (P0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " !,B&=9GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $R(9UF7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M $R(9UFJQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !,B&=9)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !,
MB&=999!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2427351d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://clearpointneuro.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>clpt-20241107.xsd</File>
    <File>clpt-20241107_lab.xml</File>
    <File>clpt-20241107_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2427351d2_8k.htm">tm2427351d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2427351d2_8k.htm": {
   "nsprefix": "clpt",
   "nsuri": "http://clearpointneuro.com/20241107",
   "dts": {
    "schema": {
     "local": [
      "clpt-20241107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "clpt-20241107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clpt-20241107_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2427351d2_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://clearpointneuro.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427351d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2427351d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-115372-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-115372-xbrl.zip
M4$L#!!0    ( $R(9UD@O03%+@,  /@+   1    8VQP="TR,#(T,3$P-RYX
M<V2U5MMRVC 0?>],_T'U:\8VAJ1I""23DDF&*6D2:"[-2T?("]%$EEQ)#J1?
M7\D7;@8*M/63O#KG[*YV5W;C=!PQ] I24<&;3N!5' 2<B)#R8=.YZ[EGO5:[
M[:#3D_?OD'D:'UP775!@81V="^*V^4 <HZ\X@CJZ! X2:R&/T3UFB;6("\I
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MAA[#-T6 XM#XH+Y1"(RA(DP7G2-=-_: >UMM\8W[Y=[(:H_\#U!+ P04
M" !,B&=9KHNS_B$7  #M@   $@   '1M,C0R-S,U,60R7SAK+FAT;>T]:WO:
MN-+?^15Z.6=WD^>$BPTD(1?.0PC)TC27!;+M]DL>80M08VS'L@/TUY\9R08;
M3"XT22]O^[1-L*31S&CNDL7!?R<CB]PS3W#'/OQ#RQ?_(,PV')/;@\,_ZIU&
MJ_7'?VN9@Z$/W:"K+0ZS0]]W]PJ%\7B<'Y?RCC<H:-5JM3#!/EG5:6^2VD\O
M%K7"Q_/W'6/(1C3';>%3VV"S01:W;U?#Q]99UYYG\417?!)-4BHL@896<SX@
MWGF[H!H37?W4KA75U8^Z<N&4=6WG(3Q4C]F R:J^&N(,%+*/1^WW\^Y^>O]Y
MUX+O45OT'6]$?5A"A%3)%?6<OAT#DA/,2 ""S_F!<_\HG-U<28O@+"U.DE)L
M[E$QX[C)%M@=S0D-,$(O11T#D1M0ZLXZ]ZGH2;!APV)GS[&82.TM6Q+=#2>P
M?6^:CDC8F!@@/'\9-#Q,0K7<>2_#8M1S'6[[-@L\)V\X(^Q<UK3B3A8UAU&S
MEB'XY\#GOL5J!P7U,W,P8CXE""?'[@)^?YAM.+;/;#_7G;K 2$-].LSZ;.(7
MI'H58%1!@3SXOUR.G'!FF7NDP_Q]<D%';(],S,D^:1W+7VZ*>N/FNO.;?GQ:
MKU_!#Z2"Y')/'%RJWB"I-RDDWD0D/AU:N3P;M,;H2O6&@>0 #?"W/F*V"?_\
M$XL.;OK4$NP9D$HQ2$T;UF+: % >M5JVR29G;'I3!#NE[U8JE>+3P6X? :>/
M;[2;4.45?'CT#!#Z36=(/29N]!MIX!0,(9\] \PQ8G(5@BHM(;0*=L\QIT3X
M4XL=9OL@>GM$*[H^Z?(1]+A@8])V1M3>4@^V8'Z/]U'"37X?#3.Y<"TZW2.V
M8S-LXY,]E%;F@0K(#]PTF8WZ@)^@UT4P CB&DO6)WV;]PVQ=7/910G*:E@,E
M(MP\S)Y0PR_B']!"&XB&N1C?2PA"MB8EX:"0@/PU<Y7C<Z6*2K8VEY6TB0MQ
MFA$-C_69!QZ6"=F.5G-/2'<(Z!#IX_:&'F*&JI>+%"4_$68V;/;!.!QF!1^Y
M%D.#$$Z3@*RF$D[@A3-!)[GL>R'QDM %XD,S%?5DDN#HX>PQ-[&ASYE').(L
MU;,T6F=)WBP.GDU62)LMG,L%1CKF$@K@VSW_F/JL-L<^@C-O6QP%HK)B3-2R
M@%)\]NA9R+X$2P.;*WZ"<BTR<<2H"#Q6"Y5P#[I$H**F!'R$E0Y<Z?,J^"'Q
MLL^:$\R-QN(DH.&P<$L,Q9%2V*GO>//69].^B%X*S-B,Q\QV1MQ^9,Y'^;$X
M:0K8J#E._B(;0]6;:YI2^=#F'11@;"V3R1RXD8D<46_ [3U2S-9^_Y>V7=P_
M*+BU%1W"IIC1;P<6RUW1@?1W<<NK1N5\Q]TC)1<\0_B@Y_B^,PJ?C;GI#]&L
M%W_+)D;W' _P5:./+&K<$ATLOW L;NZ3L#&"I-JU>3OZBIS@7\ 1P=,Y64AZ
M^'^,@D*"A&=Q)G1*NX\YI8AX  5=B_L$-39'+3Z 1P88&N8!^;W:]46KVSPF
MG6Z]V^S PO5JKSUCI]FX;K>Z+9BN?G%,FA\;?]8O3IND<7E^WNIT6I<7#Z'Q
MJ#=^*AH?J!A"@N<[,/XXW\@3O5@I5U]_Z@>7]86H>[;*6*P/T]/ =V9*X_'!
M</;L&4KS"DKQ=OQ_,2$_N6R?DP/A4ENZ%8Q)J\6R#+ISN6/'"#!@PPSGQI@E
M!//4X$OI;M#M.@-6-;8!W)J16S4>N<7GS-9V<V>+D=I! ;&MO8$)D%R)08Y$
MI!B7$8G,-\0CB<$O57J=E7P+/'ZMY%NL9"E?>2G;">%!NWG1)>WFU66[^R;!
MP%7@B8#:/O$=&&A@]4\1K97(99MHE0USDSA]X@]9YBWP 1P"C_L<(#4GQI#:
ML/YUPT<4M&JI_'-$*;T:)IQ(4YNYCN>K.3>BAXQ"CL&$3]@]C,AXL@\S-_?(
MDF/=7G"L5S)I;:J,-MW#5EL[Q;ON<5UKZ,_RL*HZ?)CE$W_/!.@CZ#LTZ70*
MZ#([Z8&U8IH'3B"7K5TX]VS48Q[9V2(XT0J__!92%RUZ[Y>Q?$)X_7;+\&HS
M_5KJKU\-O?QBJ[%@U?30JJFB:YL-N, -*A_KW>E&;70Z:$R=#JL4!VNG#9JV
M7/!-SIVM-=XWZ^VKRQ8XZ8OF=?MRB[0N&ODU,HH76Z6-Y@3PEXBC[_!F"!,J
MB'"9@?56DW#@KR\RX%'!E7B;/X4;_:6_3^2_3WL6@R;+ KDT<',_"PX:/[O4
M-*//ST8CQJY9G=!P+(NZ G@1_2;+R0>^%\&_9Y[/#6I%& -3PXKS@6^NB,33
M:)S-7RK]]F@FM&QCB@D;T[(-QX,P2VY_=WR(3QIJ?[CAF"M,SF1<MD]IB5)O
MN&X<A3OSN&7A,]=S[E&%EP(I?=DF/8AKMG;,+#J&D.S!<"K\U3>_CO/E=3A_
MDN#\";<8H AQ8#J;_[J[='L^K6C,6-^REY:Y.)\7=ZJT7*F\J^MOP;.UI/4H
MP;,NG;3"K31#2L%###S3/EZ<]([:.T?6^@Q,V0M=@42V5MG-Z:5J>5O??2([
MX3]O'2.QRB-*G2".1QS(6CWR&1)*87*9V^+4!/G;\PJU#/A+'E>F3=6<ML2K
MYFHXHQ$78@DTBA=1'%D#:BO?SG?RI#ER+6?*O"3H)->7)YFQLR#M_H_MXQ]3
MA;II>DR(\,=[;C,M70WLCQ>=B^ ?@[GF^FI065:#% 2R-4TO$EB_#F>>1TG]
MGN6!Z("#5(*S_(9Y[B(O=])XV8!?+[VN,[;3.?GE=AK<G9D?W;_X^IS<7LG)
M^?396L>QJ$W)$:/&< 7;ME9N-B2@2IMPZ5V!GP657^'2&^[EL'C4ONZ6>Z_H
MTG=6DKZ )*0;L(0 W.9T98KQ%.VX<@ CZQ-W5T<S?_H=NCWPJZ?'N^LOZNY*
MRA(89&M5O;A3^89ZL!&BA1F3ZP&ON4LMPB;,"'Q^CXD4F%>$^H6[&0-0WOQ9
M"H\;BP)3#04&U:[N,;I:1"X'^GC<8<-/EU]A01-;<_$YL[7=W54!P^:2F#=#
MK-\[$"1<#1W[P1B2W[_SQ7G_K,G7KP[HB9+FXKS9FKZ[DZMJQ>HWK07,RQ6_
M_VM7UW;V!72UF(N($EMBNH4ACQ5@UI>!+(&2GTB\?Q4$O@G_/P<"XM$IN*LA
M TY T$VH"^X/+"L&XCUG0GK,<L:$RWTD<@+NDNSFSDB?6R"&A N029_9)C,S
MOD,$'P663VWF!,*:$@%AKNA/Y<AP@-.#B57TJ[:FXF6O .!XA-K3J*WO6# Y
MCD.7S#%6%V1#,$9.F<T\,/PM&\8&,D$@];RNL-W<>R%FK2S&Q(LOB\69KRO&
MQ,^#%5/.@ZDT\[%T*Y:HA-"+V4)M^:E>SI<K$N)26MNG(VY-]\@'H MI%=FE
M&+02FO(/'O=!"#"A"NPPN1$KMK#>M<0_TS\KSO;MVEM8/<>Q&+7EH>$%2Y^H
M Z>BI99T=W]E""-_1,N..1G\"R$!AG%0Q(WMP*(I(&6]$@HQ2F]L0Q3W03>T
M'=(X:1.]5,Q#Q\UYQI>6[B7D8%D*?DGF@Y)Y'$HF9"'<@"6P!^=@S\"H6>EB
M>3WAE=OKZKL[0WL-L4R4 I=Q>II,SJ1Q#@"60$%8%D6M3'.:'I/&Q)[\3!;+
MQ;SJ^4L<7U$<HYCWRF-HC?"POSS7AH[3N^SW5T6_#4;=LV[Q8[''7D,L$[75
MU;@]4SP!4,Z(07K4:FIE,Z=O]#:?)JRJ[R]Q?45QK::+:TN(@'F/"JU_RMZU
M^G;_LKOS&D);?D!HES!\==$ML5QYPWB:Z(9]'Q'=EPE5OQY<+'I1(3KSF)G@
M0'CHC&A2><.0':A^]>C[1]D*5=#V2&\QS5P</>*F:;$9+F4-4 F)BK+:2KZ,
M5B-Z&ID-/:_''ZNL..R[QK'37JV+K[A*0N1Q-F-(#(L*\=@^6CRK7B(W; PI
M6=4<D?1<;NG;WY!;'I7E&.1&9SKJ.=:&V/R.>54J?3M>X3&<A&"QR%*"#1D/
MN3%4FV1S:_-2NXU?R=.P77%@J?6;<'/%ODEHLZ>:WI-ZG.Z@_^F?OVLUCZOF
M\?K;RGIB/VUQWFP-O3(L:\=WC-LM\N]BOJ@!\1ZYIU; B(OOH X?.NGPJ/:L
MNYC?PW+MALL56@]E.-+72EQ^_OM+FU_WW_777ZO$CEUB4CP6=]7]_[D*QPM*
M$P5N#QQ5'+P;_M4:NE\:S]N,6-QD1,.7MK^H[Z0I51RO+%A18=*[55L5#>IR
MGUKDG'JWS$^UG5'(^;U%G*F%Z? AM_'@Q![)@1V1:4W+-C$H9Z0W)88L70.L
M6_ B3)X;2=:5,UP06'F(Z'&Z 1EXSM@?8FSO8JV9"F*R/K?544M5QRM6HGAV
MH8BG7F8HD0VD?6=?UO*BSC -K)2+AS3Q"(M*$/1>3H_>PGCL#8D(*"8+\W$Q
ML/E7X;54PE6<?L4U?G#>YHK5^JJ$5FUL1Z!/)>2& IRN\732O=CY-#;N)FMK
M_$.Y;,JN>RIR3TUC7W*1WE(2'M/V_@/ZB[NB"\8@(XT!7]I?&H*J,PNR5E!U
MVY$Y;""8[ 7SRETL(J]3XC*O5==(X%K*N:PI3C[F,#4*H@UT0HO'[KF <6!
MJ&U@*98:\H(B3 OP+BN3>J90^U?FJ@2ZM$%G"73<,N2?)NZ1<+RD%+QX/>$;
MWHFP.C!9NC/A&V\ OP'7$=M]Z'T78)4+@$K497BWS,25=T?$ETC34]9H6X9<
MRW=$)"U)>,_&TNP>H[>Y'@/5 PQ=B7%\QNV4"1&+9\X87\G76\0?N;JL<5OF
M[BV?C8@&25Q>Y>1AO11:FGA\'0\!.(22:$.+'&- Q>6!K/K 8[*8&AOZ?=<^
MG^*;BOD*LN;2)M&[D J%\(7(K4P#[UZ[PKO78-; <[94>\LV\F0#[3P>\]&+
M^Z&'EY^T_4TB4QD9BB)';5+W<]TARZF GC3O H@1B*QMHS?J4 L#TXC%"<BR
M+3-KF\T@/5@':&+6%KG@AF/10"CL?J<C=Y^$*,TQ#H]9,W-+OIDDYP1U69BO
M/HC-LH7^38",JSQ?9$+O%B-7GG$R5)U J#K!O$(05@RB.@&&QA&[9G6%&45#
M>H_,H .@=8"!@$(1?*[!F"F/"@8N(O3O2C$#WM-"IYM@E<1QCGO?<T;$!PG!
M0?@3R!EZ3C! UQ\-HKZD:*16Q@F7) 2"DP\\.MI:2"_FGS)ALJ&X7-8J$ -L
ME#?5QY6'",+\0X*E(Q6R)"A)=(\HRI,Z1"R*2K3@YGR_(K,H0F/@#^DQPG$O
M)1FOI"U@%%[)0$:>GI50X .>%5+4='*0,*EC]4Y>/2J52CE]IU+>V09VR^)?
M9BQY8U@4Q9\!.PUI/WK313Y 3#6/DN:G^&<RTFDV9J+A+"JH7I0:6MJ24/'B
M2UPJ?-O.#P2>4H*5 41 $B6S16 ,5]&(>""0V'@1N*ZE6B6H"/N0:TKW)#G-
M!N*&O^(;V02R5N;T7RJ_^W8&L1/T/@,K(FD!6S92"P;9DBG#ZIDI6! \M2#2
MB"@9Q-!<;L9Y&%9;4U@&*AQ;>E,0#\?S 5T *[!:+ <!;[DO(+2'Y,O"2-Z4
M9@%FCPP")%[J=#"%=0('"+ R<D%EKSYDB7BHS*)CZ.*!<H9V$1M!" )+[0-N
MS98^UB>D2M5G%@HQ<VLH"5=ZN&1D,BB-H)IN*!B+JL;G9]V$S$JPDZ0L=C)4
MYB8N)(=HLQ X],-XEEA\A,R9OU>:%,T\N5YE$N(K,Z+3)4( $$XZ8OX0TB43
M!YE(4X\]V5HNUV!6F\7,LEG,DVZ$X8Q;\Y.&(HW[,0N[8 #1W8BY&*M#C-2(
MSBP:$#I1;F?F AWGO@'* ?H$(9%A.4(^F?7[\;5[=3;ZR(1+Q5A8KTQD%#$M
MI\A^*34N2)B2-2K5/S3N,Q]>RA=_(V&N&^K<  RPF.DXB/ZL>!=J&N@ '6%2
M+F.!N!]$)<S$E7#)X2V)AZW05 G]S&!A06*V]LBVD3U_T2LT@+['>X%\($M?
M"<$!'#,6ISUN*:E>%0$H48]81RWA*&OI,3[J >HLIJRR<J'$-:;W;.(R6S"T
M)XB4'18A) DR^L3*A0P_4\A7TR_R!&F#242,!1YS@<G0&*H@LF!,/:S#1#Y\
MKAD1KUU(,R5$,2N9JK6:+PHZ2M])<H$+6<X)-5Z)D=1W.H]Z'M!W0 7-&O5E
M?RD$(@!^H=]01^TD#1GL* W7 ]#2^8/@>\H;XDV5RW%!?&YH&G 9T([#8Z=
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MMC 5"FVQ=)P9&9)/9\(@;4,,$A8HL#EZ"S_^_CTV2HNA1DF$MA90]13DL1-
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MXV&O=Q]_Z_2BWKUN-SLO>$/0MRNS72T4)SW\ZDU/U2PRRX?UTP[8JXWL=O)
ML!E84V) _(K[1EC*4Y?VAQO8 A"#!D=5W7ML2*U^M,<BJU5A!ZRN!;;O9"0X
M&OA#QP,S8WXO9:G$':<K2PP+IVJ3K]HM@5DT[4K5'KT1."N_0F$O/>M(^A#
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MZ20M?GJX$Y;+D16C%+^_OP<7!KA<GB;5AS(K&AAF5I6&LHKA7APET7&:)[?
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M>,9_)/H!RYW8HV1RGQNCT]A12I[[$SD,[XA<&[@_SLFZ^)KNH%?*N$X:SVE
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M(5/ F#>R>@K84G8*IB'WYQW3-"1Q2TFA/BI9,)*I)0A)/+E*LJ)N0)S-30*
M:-[DH)9 ;-H0,DES;7%ZA'R[9.1B^=CFJ1*\IU(!U)957-95$(F-:6.J5N\.
M3"'BE"-U;GITXO8L,CW\&@X\ V^5A$**>!KQ4">3%!72R&F!S;4K9C(;H;".
MP(8!8P=$7)XE@RQ'4] S@0:IY>F)C.I\098\O/>@>$"#)4!4<KH!B9+EE8/
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M-LFU_#H:ZA(%S:R:1\>8Q"X%Y*JWC]DM<V$.6V+7^K:Z54WVME^GK@9<7N]
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M.<NM2VUO<2$_X8D5G1+KP@QD! CGNG%%D!CNXSI0(*.\)C^^DKF^Q$9!#3>
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MF?!S2 D,"60G]Y@03<+B55KX3=.^VZ*!P^PJ6\C7(2$HO<^HXS1:'2]3X?>
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M,IUO"GV$S3W7\(J#9T_WHU=5F8QND_D:QC?\$8C\5QAG_\D/:WB)HL[_2'"
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M?K1_$0!4F,FBNY+C.4=+39T<=9M92I,C,8&<B!C('Z(B]2>R@/#(YDB=-6<
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M+3(P,C0Q,3 W+GAS9%!+ 0(4 Q0    ( $R(9UG4I4R;_@H  ("&   5
M          "  5T#  !C;'!T+3(P,C0Q,3 W7VQA8BYX;6Q02P$"% ,4
M" !,B&=9>X$BYET'  #C5P  %0              @ &.#@  8VQP="TR,#(T
M,3$P-U]P<F4N>&UL4$L! A0#%     @ 3(AG6:Z+L_XA%P  [8   !(
M         ( !'A8  '1M,C0R-S,U,60R7SAK+FAT;5!+ 0(4 Q0    ( $R(
M9UD/ .WA;G0  (]Y @ 5              "  6\M  !T;3(T,C<S-3%D,E]E
M>#$M,2YH=&U02P$"% ,4    " !,B&=9,?HS8OD,   *,P  %0
M    @ $0H@  =&TR-#(W,S4Q9#)?97@U+3$N:'1M4$L%!@     &  8 BP$
' #RO      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2427351d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="clpt-20241107.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001285550</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-07" id="Fact000004">0001285550</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-07" id="Fact000010">2024-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-07" id="Fact000011">CLEARPOINT NEURO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-07" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-07" id="Fact000013">001-34822</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-07" id="Fact000014">58-2394628</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-07" id="Fact000015">120 S. Sierra Ave., Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-07" id="Fact000016">Solana Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-07" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-07" id="Fact000018">92075</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-07" id="Fact000019">888</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-07" id="Fact000020">287-9109</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-07" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-07" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-07" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-07" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-07" id="Fact000025">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-07" id="Fact000026">CLPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-07" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-07" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
